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Abstract
Deep vein thrombosis (DVT) and pulmonary embolism (PE) together comprise the disease state of
venous thromboembolism (VTE). Thrombi in the veins of the lower extremities (DVT) can embolize,
resulting in complete or partial occlusion of circulation through the pulmonary vasculature (PE). Despite a
common etiology between DVT and PE, the cause of embolization remains mostly unknown. Research
indicates that fibrin clot structure and functional properties are altered in VTE compared to healthy
controls. Whether these properties differ between DVT and PE subjects remains to be determined, and
may underscore possible mechanisms of embolization. Inflammation and oxidant production are involved
in the pathogenesis of VTE. However, biomarkers documenting these pathways in humans are lacking.
Elevated levels of nitrated fibrinogen have been documented during inflammatory and oxidative
challenges and may serve as a functional biomarker in VTE. Differences in fibrin clot structure and
functional properties between DVT and PE, as well as the role of nitrated fibrinogen as a biomarker of VTE
were evaluated in the plasma of subjects presenting with symptoms of VTE to the emergency department
at the Hospital of the University of Pennsylvania. Plasma fibrin clots derived from PE subjects showed
increased establishment of viscoelastic properties and faster lysis time compared with DVT. The rate and
extent of factor XIIIa crosslinking of fibrin were similar between DVT and PE. Clots from PE subjects
showed decreased fiber density and no differences in fiber bundling. Together these data suggests that
fibrin fibers are formed faster in PE subjects, possibly resulting in earlier lysis, which may lead to
instability and embolization. Nitrated fibrinogen levels were elevated in VTE positive compared to VTE
negative subjects, with no differences in fibrinogen concentration. Subjects in the highest quartile of
nitrated fibrinogen had an increased risk of VTE compared with the lowest quartile. This risk persisted
after univariate adjustment for advanced age, active cancer, and recent surgery, but not after multivariate
adjustment for all variables. Thus, nitrated fibrinogen is an oxidative risk marker in VTE, providing a novel
mechanistic link between oxidant production, inflammation, and VTE.
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ABSTRACT

The role of fibrin clot properties and fibrinogen nitration in the
pathology of venous thromboembolism.

Marissa Rose Martinez
Harry Ischiropoulos, Ph.D.

Deep vein thrombosis (DVT) and pulmonary embolism (PE) together comprise the
disease state of venous thromboembolism (VTE). Thrombi in the veins of the lower
extremities (DVT) can embolize, resulting in complete or partial occlusion of circulation
through the pulmonary vasculature (PE). Despite a common etiology between DVT and
PE, the cause of embolization remains mostly unknown. Research indicates that fibrin
clot structure and functional properties are altered in VTE compared to healthy controls.
Whether these properties differ between DVT and PE subjects remains to be determined,
and may underscore possible mechanisms of embolization. Inflammation and oxidant
production are involved in the pathogenesis of VTE. However, biomarkers documenting
these pathways in humans are lacking. Elevated levels of nitrated fibrinogen have been
documented during inflammatory and oxidative challenges and may serve as a functional
biomarker in VTE. Differences in fibrin clot structure and functional properties between
DVT and PE, as well as the role of nitrated fibrinogen as a biomarker of VTE were
evaluated in the plasma of subjects presenting with symptoms of VTE to the emergency
V

department at the Hospital of the University of Pennsylvania. Plasma fibrin clots derived
from PE subjects showed increased establishment of viscoelastic properties and faster
lysis time compared with DVT. The rate and extent of factor XIIIa crosslinking of fibrin
were similar between DVT and PE. Clots from PE subjects showed decreased fiber
density and no differences in fiber bundling. Together these data suggests that fibrin
fibers are formed faster in PE subjects, possibly resulting in earlier lysis, which may lead
to instability and embolization. Nitrated fibrinogen levels were elevated in VTE positive
compared to VTE negative subjects, with no differences in fibrinogen concentration.
Subjects in the highest quartile of nitrated fibrinogen had an increased risk of VTE
compared with the lowest quartile. This risk persisted after univariate adjustment for
advanced age, active cancer, and recent surgery, but not after multivariate adjustment for
all variables. Thus, nitrated fibrinogen is an oxidative risk marker in VTE, providing a
novel mechanistic link between oxidant production, inflammation, and VTE.
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CHAPTER 1

Introduction
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1.1 Introduction to VTE
Venous thromboembolism (VTE) is a common thrombotic disease state that encompasses
both deep vein thrombosis (DVT) and pulmonary embolism (PE). DVT is the formation
of one or more thrombi within the body’s large veins, and is usually localized to the veins
of the lower extremities. Production of these thrombi can result in partial or complete
blockage of venous circulation. As such, patients often present with symptoms and signs
of pain, swelling, discoloration, and tenderness in the affected area. One of the most
serious complications of DVT is PE, which occurs when the thrombus embolizes and
becomes lodged within the pulmonary vasculature, partially or completely blocking a
pulmonary artery or branch. In this way, DVT and PE are two disease states related by a
common origin, which subsequently diverge due to distinct mechanisms that have yet to
be determined.
1.1.1 Prevalence of VTE
VTE affects around 1 per 1000 people per year within the United States, with increasing
incidence for congenital and acquired thrombophilic risk factors (Anderson et al., 1991).
Using computer modeling, it is estimated that over 900,000 events of incident or
recurrent, fatal and non-fatal VTE occur annually within the U.S., more than either
myocardial infarction or stroke (Heit et al., 2005). History of DVT is itself a risk factor
for a second episode, as 30 % of patients experience a recurrent event within 10 years,
with the greatest risk within 6-12 months after the initial event (Heit et al., 2000a,
Schulman et al., 2006). Patients with recurrent VTE are also more likely to experience
the same type of occurrence as the incident event (Schulman et al., 2006, Anonymous
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1997). Thirty percent of VTE cases die within three months (Heit et al., 1999). Although
DVT is not a significant cause of death, a longitudinal study investigating the etiology of
VTE found that 9 % of cases of DVT resulted in death (Cushman et al., 2004), and
modeling for both hospital and community based DVT estimate that over 2200 deaths per
year are attributed to DVT (Heit et al., 2005). PE is the most significant cause for
mortality within VTE, with epidemiological studies indicating that 23 % of patients die
immediately from PE, and an additional 25 % die within 3.5 years (Anderson et al.,
1991). Together, DVT and PE are estimated to account for between 100,000 and 180,000
deaths each year within the United States (Rathbun., 2009).
1.1.2 Pathophysiology of VTE
The formation of thrombi in either the arterial or venous systems is due to aberrant
activation of the coagulation system, likely due to some combination of changes in blood
flow, endothelial activation or disruption, and a hypercoagulable state, as Virchow
described (Virchow., 1856). Unlike arterial thrombosis, venous thrombosis occurs in the
absence of endothelial denudation or apparent damage (Schaub et al., 1984, von Bruhl et
al., 2012), suggesting that the other initiators of thrombosis described above, as well as
participation from inflammatory mediators play a more central role in VTE pathology
(Schaub et al., 1984, Sevitt., 1974). DVT often occurs in areas of stasis or disturbed
blood flow such as in valve pockets or sinuses (Sevitt., 1974). To maintain quiescent
conditions, endothelial cells produce and secrete factors that prevent cell adhesion and
activation of coagulation, including thrombomodulin, protein C, prostacyclin, and nitric
oxide. Although the central cause of VTE remains unknown it is clear that during VTE
endothelial cells become activated resulting in the surface expression of adhesion
3

proteins such as P-selectin and von Willibrand factor (von Bruhl et al., 2012, Myers et al.,
2002, Palabrica et al., 1992, Geng et al., 1990, Wakefield et al., 1995). Neutrophils and
monocytes express P-Selectin Glycoprotein-1, and are subsequently recruited to Pselectin expressing endothelial cells (von Bruhl et al., 2012, Myers et al., 2002, Palabrica
et al., 1992, Geng et al., 1990, Wakefield et al., 1995). Upon binding to these proteins,
neutrophils, and monocytes become activated and shed tissue factor bearing
microparticles that contain anionic membranes capable of assembling the coagulation
cascade complexes (Figure 1-1) (von Bruhl et al., 2012, von Bruhl et al., 2012,
Hrachovinova et al., 2003, Biro et al., 2003, Jy et al., 1995). Ultimately, fibrin is formed
in the last step of the coagulation cascade, producing a thrombus composed mainly of
fibrin and leukocytes with some platelets and trapped erythrocytes (Schaub et al., 1984,
von Bruhl et al., 2012, Sevitt., 1974, Palabrica et al., 1992, McGuinness et al., 2001).
Alternatively in VTE, thrombi can also have two distinct cellular compositions. Thrombi
near the site of initiation are red, composed mainly of erythrocytes and fibrin, and
thrombi downstream of the initiation site are white, composed of mainly platelets and
some fibrin (Sevitt., 1974). The thrombus can fully or partially abrogate blood flow
through the vein resulting in pain, swelling, and discoloration in the affected area.
During and following thrombus formation, cellular factors work to resolve the thrombus,
which resembles wound healing. The formation of fibrin, in either soluble or fiber form
(Rakoczi et al., 1978, Garman and Smith., 1982, Thorsen et al., 1972), acts as a cofactor
for tissue plasminogen activator (tPA) cleavage of the serine protease plasminogen,
forming a ternary complex that produces plasmin and results in the degradation of the
fibrin clot (Hoylaerts et al., 1982). Although leukocytes are capable of endothelial
4

damage during chemotaxis and subsequent diapedesis, they are also required for
thrombus resolution (Stewart et al., 1974). Neutrophils are the first cells to invade the
thrombus, and they function to degrade collagen and fibrin (Varma et al., 2003). Their
depletion during thrombus resolution results in larger thrombi (Varma et al., 2003).
Similar results are seen with macrophages where direct administration of peritoneal
macrophages decreased thrombus size by more than fivefold and deletion of the
monocyte attractant chemokine, CCR2, inhibited monocyte recruitment and thrombus
resolution (Ali et al., 2006).
Upon embolization, the thrombus can become lodged in a pulmonary artery or branch,
with smaller thrombi traveling farther through the vasculature (Pryce and Heard., 1956).
Large emboli can completely abrogate blood flow, and may result in death due to
insufficient blood flow to fill the left side of the heart and maintain systemic arterial
pressure (Corrin and Nicholson., 2011). Large and small emboli can both result in
complete or partial infarction, which is necrosis of the tissue distal to the site of embolic
obstruction. Complete infarction is rare and thought to require congestion in the lungs
due to conditions such as heart disease (Dalen et al., 1977). Complete infarction can be
healed by repair mechanisms similar to those described for DVT accompanied by the
production of scar tissue (Corrin and Nicholson., 2011). Partial infarction is much more
common and is characterized by edema, followed by capillary rupture and a filling of the
alveoli with blood (Corrin and Nicholson., 2011). These infarcts are resolved within a
few days, and usually little to no production of scar tissue is evident (Corrin and
Nicholson., 2011).
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Although the cause of embolization remains unknown, the location of the thrombus is
associated with risk for PE. Deep veins of the lower extremities include the veins above
the knee i.e. proximal and those veins below the knee or distal. Proximal veins include
popliteal, femoral, or iliac and distal veins include tibial, peroneal, and the muscular calf
veins, soleal and gemellar. Distal DVT is rarely associated with symptoms (Ciuti et al.,
2012), while 88 % of patients with symptomatic DVT have thrombi localized to the
6

proximal veins (Cogo et al., 1993). Proximal, and not distal DVT, is frequently
accompanied by PE (Moser and LeMoine., 1981). In one early study, PE occurred in 0 of
31 subjects with distal DVT, whereas in subjects with proximal vein thrombosis, PE
occurred in 4 of 9 subjects (Kakkar et al., 1969). Furthermore, in symptomatic DVT
subjects without chest symptoms of PE, 40 % had evidence of PE upon lung scanning
(Moser et al., 1994). Nearly 100 % of subjects with proximal DVT also had evidence of
distal DVT, indicating that thrombosis starts in the calf veins and propagates to the
proximal veins, whereby it may embolize.
1.1.3 VTE diagnosis
DVT is diagnosed by several imaging techniques, but the reference standard is contrast
venography. To view the entire deep venous system, iodinated contrast agent is injected
into the dorsal foot vein and lack of venous filling is an indicator of DVT (Bates et al.,
2012). Contrast venography is highly sensitive (95 %) and specific (92 %) (Killewich et
al., 1989), but is expensive, invasive, and contraindicated in patients with renal disease
and allergy to contrast media (Lensing et al., 1990). Thus, the utility of non-invasive
diagnostic tests are preferentially used during diagnosis of DVT. Clinical probability
scoring is used in the primary analysis of likely DVT and is recommended by the
American College of Chest Physicians as the first assessment for diagnosis. Wells pretest
probability scoring is the most widely used and takes into account signs, symptoms and
risk factors for DVT and assigns a low, moderate or high probability (Wells et al., 1997).
Following a low pretest probability, D-dimer testing is recommended. D-dimers are a
crosslinked fibrin degradation product produced during the intravascular thrombosis and
thrombolysis (Figure 1-1) (Ruckley et al., 1970). Several assays have been developed for
7

the rapid measurement of these products in both plasma and blood. These include
qualitative assays such as whole blood agglutination (John et al., 1990) and quantitative
assays such as latex agglutination (Elms et al., 1986), and enzyme-linked immunosorbent
(ELISA) or immunofluorescence (ELFA) assays (Whitaker et al., 1985). Agglutination
assays rely on monoclonal anti-D-dimer antibody linked red blood cells or latex beads
that aggregate in the presence of antigen (D-dimer) (Elms et al., 1986). The ELISA and
ELFA assays also utilize monoclonal anti-D-dimer antibodies in a multi-well format
coupled with either chemiluminescence or fluorescence detection (de Moerloose et al.,
1996, Bounameaux et al., 1991). Compared to latex (57-100 %) and whole blood
agglutination (53-100 %), ELISA (71-100 %) and ELFA (88-100 %) have the highest
sensitivity. Specificity remains low in all tests (Di Nisio et al., 2007), which is partly
attributed to the high number of non-thrombotic conditions, including pregnancy, cancer,
infection etc. (Francalanci et al., 1995, Hafter et al., 1985, Kuller et al., 2008) that also
suffer from increased D-dimer levels. Because of this, D-dimer is used as an exclusionary
test, with patients below a certain D-dimer level precluded from VTE. Recent efforts
have been made to identify additional markers of VTE to aid in non-invasive diagnosis,
including coagulation and inflammatory factors such as factor XI, c-reactive protein, and
myeloperoxidase (MPO) (Cushman et al., 2009, Kucher et al., 2003b, Nordenholz et al.,
2008, Mitchell et al., 2008, Martinez et al., 2012). Studies on MPO have shown that
elevated MPO is not only is a risk factor for VTE, but moderately improves upon the
specificity of D-dimer for VTE diagnosis (59 % vs. 73 %) (Nordenholz et al., 2008,
Mitchell et al., 2008). Nonetheless, identification of additional markers of VTE may help
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explain the underlying etiology or pathology of VTE, and may also prove to be useful in
future diagnostic marker of the disease.
Due to its non-invasive nature and high accuracy, the most commonly used imaging
modality for DVT diagnosis is ultrasound (US). Distal DVT is not usually associated
with PE or other clinically adverse events, and thus compression US (CUS) is often used
and focused primarily on the proximal veins such as femoral and popliteal. The inability
to collapse the vein under pressure is indicative of DVT by CUS (Bates et al., 2012),
which has a high sensitivity (97 %) and specificity (86 %) (Heijboer et al., 1992). For
patients diagnosed with distal DVT, it is often recommended that the patient receive
additional follow-up US 5-7 days following the initial US to ensure that thrombosis has
not extended to the proximal veins (Bates et al., 2012).
Both clinical probability scoring and D-dimer levels are also used as initial non-invasive
tests for PE diagnosis. A high or moderate likelihood of PE requires subsequent use of
imaging, of which computed tomographic pulmonary angiography (CTPA) is the
accepted standard of care. In CTPA the patient receives an iodinated contrast agent that,
upon scanning will show filling, or in the case of embolism, a defect in filling of the
pulmonary vessels. A recent meta-analysis indicates that sensitivity of CTPA alone is
comparable to CTPA plus additional CUS in identifying PE (97.4 % with vs. 97.3 %
without CUS) (Mos et al., 2009). This study also demonstrated high negative predictive
value (98.8 %) for CTPA indicating that overall, CTPA alone is sufficient to accurately
identify positive and negative PE patients (Mos et al., 2009).
1.1.4 Antithrombotic therapy for VTE
9

Treatment modalities are similar for DVT and PE patients. Therapy for VTE targets the
coagulation cascade, supporting a main role for fibrin rather than platelets in VTE.
Heparin is a standard first line treatment for acute VTE. It functions to bind and activate
antithrombin III causing a conformational change, which results in the inhibition of
thrombin, factor IXa, and factor Xa (Figure 1-1) (Chuang et al., 2001). Heparin is a
heterogeneous mixture of highly sulfated glycosaminoglycans and comes in two main
types, unfractionated heparin (UFH), which is composed of polysaccharides ranging in
size from 5-40 kDa and low molecular weight heparin (LMWH), which contains only
polysaccharides equal to or less than 8 kDa (Lane et al., 1979). Homogenous
polysaccharides such as fondaparinux function in a similar manner to the other heparin
derivatives, but are less frequently used due to cost. UFH and LMWH have both been
shown to resolve acute thrombosis and prevent recurrent VTE to similar degrees (Kearon
et al., 2006), but LMWH has decreased risk for osteoporosis and heparin-induced
thrombocytopenia (Monreal et al., 1994, Martel et al., 2005), and thus is recommended as
initial antithrombotic treatment in VTE (Kearon et al., 2012) . Initial therapy for VTE
usually proceeds for 5-10 days followed by long-term therapy for 3-6 months. The goal
of long-term therapy is the complete resolution of the thrombus during the initial episode
of VTE and to prevent recurrence. During this phase of treatment, patients are usually
switched to vitamin K antagonists such as warfarin. Warfarin inhibits the enzyme vitamin
K epoxide reductase, preventing vitamin K production (Magnusson et al., 1974). The
coagulation factors VII, IX, X, prothrombin, protein S, and protein C require vitamin K
for the conversion of glutamic acid to γ-carboxyglutamic acid, which is essential for
calcium binding of phospholipid membranes (Furie et al., 1979). Continuation of therapy
10

past 6 months may be required in those where the risk of VTE remains either unknown as
in idiopathic VTE, or ongoing as in cancer (Kearon et al., 2012). Patients with proximal
DVT or PE are recommended for treatment as described above. However, patients with
distal DVT without indication of risk factors for extension to proximal DVT are not
recommended for treatment due to the high risk of bleeding outweighing benefits of
anticoagulant therapy (Kearon et al., 2012).
1.2 Fibrinogen and clot formation
Fibrinogen is a 340 kDa protein involved in the end steps of the coagulation cascade
(Figure 1-2). It is produced in liver hepatocytes and secreted into the blood (Whipple and
Hurwitz., 1911), where it circulates with a half-life of about 3 days (Stein et al., 1978).
Fibrinogen is composed of two pairs of three non-identical chains termed Aα, Bβ, and γ.
Each chain is encoded by a different gene, all of which reside on chromosome 4 (Kant et
al., 1983, Crabtree and Kant., 1982, Olaisen et al., 1982, Humphries et al., 1984).
Together the chains comprise a symmetrical molecule composed of one globular E region
flanked on each side by globular D regions (D-E-D) (Figure 1-2) (Hall and Slayter., 1959,
Kollman et al., 2009, Yang et al., 2001, Brown et al., 2000). The central E region is
connected to each of the D regions by triple helical coiled-coils comprised of the Aα, Bβ,
and γ chains (Figure 1-2) (Kollman et al., 2009, Yang et al., 2001, Brown et al., 2000).
The chains are held together by 5 symmetrical disulfide bonds and an asymmetrical
disulfide ring (Blomback et al., 1976, Huang et al., 1993). The N-termini of the Aα, Bβ,
and γ chains are all located in the E region and comprise the central nodule (Blomback et
al., 1976, Zhang and Redman., 1992). The D regions are comprised of β and γ nodules
formed from the carboxy terminal portions of the β and γ chains, respectively (Figure 111

2) (Yee et al., 1997). The carboxy terminal portion of the α chain contains an
independently folded compact domain called the αC domain (Burton et al., 2007) that is
tethered amino terminally to a flexible region termed the αC connector (Tsurupa et al.,
2002, Medved et al., 1983). The αC region and connector are hypothesized to be highly
flexible and unable to be crystalized. Thus, they are not represented in Figure 1-2. The Ntermini of Aα and Bβ chains contain fibrinopeptides A (FpA) and B (FpB) (Figure 1-3)
(Kollman et al., 2009, Yang et al., 2001, Brown et al., 2000). Thrombin cleavage of these
peptides exposes ‘A’ and ‘B’ knobs, resulting in the formation of fibrin monomers
(Lorand., 1951, Blomback et al., 1978, Blomback et al., 1972, Bettelheim., 1956,
Budzynski et al., 1983). ‘A’ and ‘B’ knobs are positively charged and have
complementary negatively charged binding sites within the γ and β nodules in the D
region of adjoining monomers termed ‘a’ and ‘b’ holes (Figure 1-3) (Pratt et al., 1997,
Spraggon et al., 1997). Knob-hole associations each result in the formation of halfstaggered, double stranded protofibrils (Krakow et al., 1972, Fowler et al., 1981), which
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then associate laterally to form fibrin fibers (Krakow et al., 1972, Hewat et al., 1983) and
a branching network (Hantgan and Hermans., 1979). The number of protofibrils as well
as the number of aggregated fibers together determine fiber diameter (Weisel., 1986,
Weisel and Nagaswami., 1992). FpA release occurs at a faster rate than FpB (Blomback
et al., 1976, Nossel et al., 1974) and thus, A:a interactions largely dictate fibrin
polymerization rates. FpB release is not required for fibrin polymerization, but B:b
interactions do function to align D-regions during polymerization, contributing to lateral
aggregation and fiber formation, and also preventing the dissociation of protofibrils
(Blomback et al., 1978, Shainoff and Dardik., 1983). As a consequence, in the absence of
FpA release, B:b interactions alone result in thicker fibers and a more porous structure
(Mosesson et al., 1987).
1.2.1 Factor XIII and fibrin crosslinking
Factor XIII (FXIII) is a transglutaminase that crosslinks fibrin subunits, providing
stability and elasticity to the clot (Figure 1-1) (Gerth et al., 1974, Brown et al., 2009,
Lorand and Jacobsen., 1962, Collet et al., 2000). FXIII is a heterotetrameric protein
composed of two sets of A and B homodimeric domains (Schwartz et al., 1971). The A
domains function as carriers of the B domains (Chung et al., 1974), which are activated
by thrombin through cleavage of the N-terminal activation peptide (Nakamura et al.,
1975). Activated FXIII crosslinks fibrin via the formation of ε-(γ-glutamyl) lysine bonds
between γ-Gln398 and γ-Lys406 on each of the γ chains (Wang., 2011), creating γ-dimers.
α-polymer crosslinks are formed primarily between α-Gln328, α-Gln366 and α-Lys556 and
α-Lys580 (Sobel and Gawinowicz., 1996, Cottrell et al., 1979). α-γ heteropolymers are
also formed with γ-Lys406 and α-Gln328 and/or α-Gln366 (Sobel and Gawinowicz., 1996).
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1.2.2 Fibrinolysis
tPA is a serine protease involved in fibrinolysis. The main function of tPA in hemostasis
is to activate the zymogen precursor, plasminogen by cleavage of Arg561-Val562,
generating the active serine protease, plasmin (Robbins et al., 1967). This occurs when
tPA binds to fibrin at sites Aα148-160 and γ312-324, which are exposed during fibrin
polymerization (Schielen et al., 1991a, Schielen et al., 1991b). Subsequently,
plasminogen is recruited and forms a ternary complex with tPA and fibrin, which
increases the catalytic efficiency of tPA activation of plasminogen to plasmin (Hoylaerts
et al., 1982). Both tPA and plasminogen have preferential binding to fibrin over
fibrinogen (Hoylaerts et al., 1982) preventing unwarranted degradation of fibrinogen in
circulation. Plasmin binds and cleaves fibrin at high-affinity lysines located in the αC
region (Bok and Mangel., 1985, Tsurupa and Medved., 2001), subsequently exposing
additional lysine residues that plasmin further cleaves into smaller fragments (Bok and
Mangel., 1985). Plasmin cleavage produces fibrin degradation products of various sizes
and compositions, most notably X, Y, D, D-dimer, and E (KOPEC et al., 1973, Gaffney
et al., 1980). Endogenous inhibitors of fibrinolysis target both tPA and plasmin, and
include plasminogen activator inhibitor-1 (PAI-1), α2-antiplasmin (α2-PI), and thrombinactivatable fibrinolysis inhibitor (TAFI). FXIII, while not an actual inhibitor of
fibrinolysis, does reduce fibrinolytic potential by crosslinking of fibrin fibers as well as
crosslinking α2-PI to fibrin fibers (Lorand and Jacobsen., 1962, Gormsen et al., 1967).
1.2.3 Fibrin clot structure and functional properties in thrombotic disease
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The role of the clot and its components has been evolutionarily optimized to prevent
bleeding and maintain hemostasis. However, many environmental and genetic factors can
predispose the clotting process towards a prothrombotic phenotype (Uitte de Willige et
al., 2005, Parastatidis et al., 2008). Furthermore, many studies have suggested that
changes due to factors such as plasma constituents, fibrinogen variants and posttranslational modifications affect fibrin clot structure and functional properties and
present as thrombotic risk factors (Parastatidis et al., 2008, Konings et al., 2011, Gersh et
al., 2009). In general, fibrin clot structures with increased fiber density, decreased fiber
diameter, and decreased porosity have generally been associated with diminished lysis
(Collet et al., 2000) and are considered as a risk factor for thrombosis (Collet et al.,
2006). Although individual thin fibers are lysed faster than thicker fibers, clots that are
composed of thin fibers with increased fiber density lyse more slowly than clots
composed of thick fibers of decreased fiber density (Collet et al., 2000). This is likely due
to the lateral transection of plasmin across fibers rather than uniform digestion from the
outside in of a fiber (Collet et al., 2000). Also, tPA is a limiting constituent during lysis,
and clots with decreased fiber density have a higher tPA to fiber ratio, resulting in
increased lysis (Bannish et al., Accepted b, Bannish et al., Accepted a). Denser clots also
tend to have increased elastic (G’) and viscous (G”) properties (Collet et al., 2006,
Roberts et al., 1974, Ryan et al., 1999), which are measures of stiffness and
deformability, respectively. These two properties may be especially important with
regards to embolization. Within the vessel, blood flow exerts shear stress on the
thrombus. Clots that are less capable of withstanding those shear forces may be more
amenable to embolization. It is unclear whether clots that are stiffer would be more or
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less likely to embolize, as increased stiffness might impart stability or strain-hardening
and brittleness. Similarly, clots that are more viscous may deform better under shear or
might be very unstable and friable.
1.2.3.1 Fibrin clot properties in arterial disease
Previous studies investigating the effects of fibrin clot structure and functional properties
have mainly focused on arterial thrombotic diseases. Compared to healthy age-matched
controls, clots derived ex vivo from the plasma of subjects with premature CAD with a
past history of acute coronary syndrome, exhibited increased fiber density, decreased
porosity, fiber diameter and length. Plasma clots from these subjects also exhibited
increased final clot stiffness and diminished clot lysis (Collet et al., 2006). Fibrin clot
stiffness and length were independently correlated with both lysis and CAD, providing
further evidence that clot structure is related to both functional properties and disease
risk. In addition, recent studies have shown that plasma fibrin clot structure and
functional properties are related to in vivo thrombus composition. In 45 ST-segment
elevation myocardial infarction subjects both thrombus structure, including fibrin,
cholesterol, and cellular components, as well as plasma fibrin clot properties were
measured (Silvain et al., 2011). The structural components measured from in vivo-excised
thrombi correlated with clot properties derived from ex vivo created plasma clots,
including the elastic component and lysis time. In addition, fibrin was a main component
of the thrombus (60 %) and was positively correlated with ischemic time. These data
support the relevance of ex vivo plasma clots structure and functional properties with
relation to thrombotic pathology.
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1.2.3.2 Fibrin clot properties in venous thromboembolic disease
Fibrin clot properties have begun to be evaluated in VTE. In a recent study, VTE subjects
showed diminished lysis and decreased clot permeability compared to healthy controls
(Lisman et al., 2005, Undas et al., 2009), similar to what has been shown in CAD (Collet
et al., 2006). In a sub-analysis of the data, the authors also show that PE subjects have
enhanced clot lysis and increased permeability compared to DVT subjects (Undas et al.,
2009). These data suggest that fibrin clot structure and functional properties may be
different between DVT and PE patients. Because DVT and PE share a common
pathogenesis with divergent outcomes, identifying differential clot properties may
underscore the mechanisms that regulate embolization.
1.3 Production of reactive oxygen and nitrogen intermediates in inflammation
Reactive oxygen and nitrogen intermediates are produced during inflammatory processes.
This includes the production of superoxide (O2·-) by the enzymes NADPH oxidase and
xanthine oxidase, located in neutrophils and endothelial cells, respectively (McCord and
Fridovich., 1968, Babior et al., 1976). Superoxide can undergo dismutation reaction by
superoxide dismutase, generating hydrogen peroxide (H2O2) and water (McCord and
Fridovich., 1969, Klug et al., 1972). Hydrogen peroxide can be reduced to the more
potent oxidant, hydroxyl radical (·OH) and hydroxide ion (OH-) by Fe (II) through
Fenton chemistry (Fenton., 1894), or oxidized to hypochlorous (HOCl) or hypobromous
(HOBr) acids by peroxidase enzymes located in leukocytes (van Dalen et al., 1997,
Klebanoff and Shepard., 1984).
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The small, free radical, gaseous molecule, nitric oxide (·NO) is produced constitutively
by many cell types, but also at heightened levels in response to inflammation (Furchgott
and Zawadzki., 1980, Furchgott and Bhadrakom., 1953, Ignarro et al., 1987, Palmer et
al., 1987). Nitric oxide can react with other free radicals including superoxide to produce
the potent oxidant, peroxynitrite (ONOO-) and its conjugate acid, peroxynitrous acid
(ONOOH) (Reaction 1) (Gryglewski et al., 1986, Beckman et al., 1990). Peroxynitrous
acid can undergo homolytic fission to generate hydroxyl radical and nitrogen dioxide
(·NO2) (Reaction 2) (Beckman et al., 1990), which are capable of oxidation and nitration
of proteins and lipids (Prutz et al., 1985). Despite this, it is more likely that under
physiological conditions (Beckman et al., 1990) peroxynitrite reacts with the high levels
of dissolved carbon dioxide (1-5 mM) to form the intermediate nitrosoperoxycarbonate
(ONOOCO2-) (Reaction 3) (Gow et al., 1996, Lymar and Hurst., Denicola et al., 1996).
The homolytic cleavage of this intermediate produces nitrogen dioxide and carbonate
radical (CO3·-) (Reaction 4) (Goldstein and Czapski., 1999), which are also capable of
nitration and oxidation reactions. Peroxidases such as MPO and eosinophil peroxidase are
also able to oxidize nitrite, producing the nitrative intermediate, nitrogen dioxide (van der
Vliet et al., 1997).
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1.3.1 Modifications of tyrosine residues by nitrative species
The peroxidase/nitrite pathway or nitrosoperoxycarbonate decomposition result in the
formation of nitrogen dioxide as described above.

In one proposed mechanism of

nitrotyrosine formation, tyrosyl radical is produced by oxidation of tyrosine by either
nitrogen

dioxide,

hydroxyl

radical,

or

carbonate

radical,

in

the

case

of

nitrosoperoxycarbonate decomposition (Santos et al., 2000). Subsequently, radicalradical recombination by tyrosyl radical and nitrogen dioxide produce nitrotyrosine
(Figure 1-4) (Prutz et al., 1985).
Not all tyrosines are capable of becoming nitrated. The secondary protein structure is an
important determinant of which tyrosines become modified. Surface exposure of the
tyrosine residue, location of the tyrosine within a loop structure, proximity to negative
charges, and proximity to metal centers aid in the specificity of tyrosine nitration (Souza
et al., 1999). The physiologic and pathologic yields of nitration are low (10-100 μmol
nitrotyrosine/ mol tyrosine), corresponding to 1 to 10 tyrosines nitrated for every 100,000
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(Parastatidis et al., 2008, Brennan et al., 2002, Shishehbor et al., 2003). Because of this
low yield, the biological significance of tyrosine nitration has been questioned. Often,
post-translational modification of a protein that results in a loss of function requires a
significant percentage of protein molecules to be modified. However, several proteins
exhibit gain of function effects upon nitration, including actin and fibrinogen (Parastatidis
et al., 2008, Aslan et al., 2003, Vadseth et al., 2004). Interestingly, both proteins are
involved in polymerization reactions. Here, the addition of a few modified protein
molecules enhances protein-protein interactions, and greatly affects the rate of
polymerization (Parastatidis et al., 2008, Aslan et al., 2003, Vadseth et al., 2004). In
fibrinogen, Tyr292 and Tyr422 were found to be nitrated in the plasma of smokers. These
residues are located in the carboxyl termini of the β chains of fibrinogen near holes 'b’
and nitration may function to enhanced lateral aggregation (Parastatidis et al., 2008).
Elevated nitrated fibrinogen levels increased the rate of fibrin polymerization and were
positively correlated with the clot viscoelastic properties, elastic and viscous moduli, and
inversely correlated with fibrinolysis rate (Parastatidis et al., 2008). These clots also
exhibited increased fiber density and fiber clustering. Thus, nitration of a few protein
molecules can indeed affect protein function and may have significant biological
consequences.
1.3.2 Tyrosine nitration plays a role in inflammation
Leukocytes are key mediators of the immune response against foreign pathogens, but also
play a role in chronic disease states such as atherosclerosis and VTE. Neutrophils,
monocytes and macrophages all contain the enzyme MPO. In neutrophils, MPO is
localized to azurophilic granules, and in monocytes and macrophages it is localized to
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lysosomal granules (Nichols et al., 1971, Bos et al., 1978). Upon activation, these
leukocytes degranulate and release MPO into the extracellular space (Leffell and
Spitznagel., 1974). MPO catalyzes the reduction of hydrogen peroxide, followed by the
oxidation of halides (Cl-, Br-) to produce hypochlorous and hypobromous acids (van
Dalen et al., 1997, Klebanoff and Shepard., 1984). These acids function as oxidants
aimed at killing foreign pathogens. In addition, these cells produce nitric oxide through
the both the constitutive and inducible forms of nitric oxide synthase (Wallerath et al.,
1997), and are capable of producing the oxidative post-translational modification,
nitrotyrosine through MPO oxidation of nitrite (NO2-). Nitrotyrosine has classically been
a hallmark of peroxynitrite formation. However, more recent studies also indicate MPO
as a key producer of nitrotyrosine. In an inflammatory challenge model of C. albicans
administration, nitrotyrosine formation was markedly increased in wild-type, but not
MPO-/-

mice

(Brennan

et

al.,

2002).

Neutrophils

activated

with

12-D-

tetradecanoylphorbol-13-acetate released MPO from their granules, which subsequently
transcytosed to the subendothelial matrix, colocalizing with and nitrating fibronectin
(Baldus et al., 2001). This effect was absent in enoxaparin treated mice, which prevented
MPO transcytosis. Thus, the release of MPO into the extracellular space may serve as a
mechanism by which circulating proteins become nitrated.
The production of reactive oxygen and nitrogen species in inflammation has been
extensively studied, and nitrotyrosine has been identified as both a marker and a
functional modifier of proteins during inflammatory processes. In one study,
lipopolysaccharide was administered to healthy human subjects and resulted in increased
production of protein mediators of inflammation TGF-β, c-reactive protein, and MPO
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(Heffron et al., 2009). Nitrated fibrinogen was also increased in this challenge model,
peaking at 72-hrs post-injection, much later than the other inflammatory mediators. In
addition, nitration of fibrinogen post-LPS injection resulted in increased rate of clot
formation. This study implies that 1) nitration results as a direct consequence of
inflammatory challenge, 2) nitrating intermediates are produced for prolonged periods of
time following insult, and 3) tyrosine nitration effects protein function, specifically
fibrinogen, which provides further evidence for the role of inflammation in thrombotic
disorders.
Peroxynitrite has been extensively studied and found to play a role in inflammatory
processes, including, but not limited to the nitration of protein tyrosine residues. In
response to cellular activation, peroxynitrite is produced by endogenous nitric oxide
formation in macrophages (Ischiropoulos et al., 1992). Peroxynitrite can inhibit cellular
respiration in macrophages, producing DNA double-strand breaks, resulting in
cytotoxicity associated with macrophage infiltration during inflammation (Szabo and
Salzman., 1995). Peroxynitrite also activates Erk through the MAP kinase pathway,
resulting in increased expression of αMβ2 on neutrophils and induces integrin dependent
adhesion of neutrophils to endothelial cells (Zouki et al., 2001). Some studies have
suggested that nitric oxide released from endothelial cells into the vascular lumen can
interact with superoxide produced by activated neutrophils, producing peroxynitrite
(Sohn et al., 2003). This could result in the production of nitrated and oxidized proteins
within vascular circulation or in close proximity to the site of neutrophils or possibly
macrophages.
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Monoclonal and polyclonal antibodies to nitrated proteins, peptides and nitrotyrosine
have been produced in mice and rabbits (Heijnen et al., 2006). This suggests that in vivo
nitrotyrosine may be a target for endogenously produced anti-nitrotyrosine antibodies.
Indeed, antibodies have been detected that recognize nitrated epitopes in acute lung
injury, as well as in atherosclerotic lesions and the circulation of CAD patients (Thomson
et al., 2007). Furthermore, in lymphoid tissues, antigen presenting cells displayed nitrated
peptides by MHC class II molecule I-A, eliciting a CD4 T-cell response (Herzog et al.,
2005). This indicates that the production of nitrotyrosine elicits an immune response in
acute lung injury and CAD, and may have indications in other diseases where nitrated
proteins have been identified, such as VTE.
1.3.3 Tyrosine nitration in VTE
VTE is a thrombotic disease mediated by inflammation. Neutrophils and monocytes
home to activated endothelial cells and are primary constituents of the thrombus in VTE
(von Bruhl et al., 2012, Myers et al., 2002, Palabrica et al., 1992, Geng et al., 1990,
Wakefield et al., 1995). As described above, these cells are capable of producing nitrating
intermediates and thus may function as cellular sources of tyrosine nitration.
Proinflammatory cytokines such as IL-1β and TNFα are increased during VTE (Reitsma
and Rosendaal., 2004) and are also known to induce nitric oxide expression either
through eNOS or iNOS in endothelial or inflammatory cells (Busse and Mulsch., 1990).
Thus, the over production of nitric oxide may facilitate its conversion to a nitrating
intermediate. Studies with LPS injection into humans, an inflammatory process mediated
by neutrophils and monocytes (Rivers et al., 1975, Boggs et al., 1968), produces
increased levels of nitrated fibrinogen (Heffron et al., 2009). Furthermore, other
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inflammatory thrombotic conditions, such as CAD and those at risk for thrombotic
disease, like smokers have elevated nitrated fibrinogen levels within their respective
patient population (Parastatidis et al., 2008, Vadseth et al., 2004). Thus, VTE patients
may exhibit increased nitrated fibrinogen levels during acute thrombosis, which may
represent a novel biomarker for VTE.
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1.4 Specific Aims
Aim 1: Evaluate clot structure and functional properties in DVT and PE subjects,
specifically focusing on those properties that might be involved in embolization.
Hypothesis: PE subjects exhibit unique clot structure and functional properties
separate from DVT that that lead to instability and embolization.
DVT and PE are two pathological manifestations of the same disease, VTE. Thus far, the
cause of embolization remains unknown. Research indicates that fibrin clot structure and
functional properties are involved in both arterial and venous thrombotic disease and
represent risk factors with pathological consequences. Furthermore, these properties may
affect the ability of the clot to withstand shear forces within the vessel wall. Properties
that are likely to be involved in embolization including viscoelastic properties, clot
formation and lysis time, FXIII crosslinking and clot structure will be evaluated towards
this end. Identification of differences in structure and functional clot properties between
DVT and PE subjects may elucidate the mechanisms that regulate embolization.

Aim 2: Measure nitrated fibrinogen levels in VTE subjects, evaluating its role as a
biomarker and risk factor for VTE.
Hypothesis: Nitrated fibrinogen levels are elevated in VTE, representing a unique
marker of oxidative stress, inflammation, and coagulation in VTE.
VTE is a thrombotic disease characterized by activation of the coagulation cascade,
production of inflammatory mediators, and the generation of oxidative and nitrative
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intermediates. Thus far, specific markers of these processes in VTE are lacking. Previous
studies have identified nitrated fibrinogen as not only a marker of these processes in CAD
and smokers, but also involved in alterations in clot structure and function. Herein we
evaluate the role of nitrated fibrinogen as a unique biomarker in VTE with specific
pathological relevance to the disease.

.

27

CHAPTER 2

Increased fibrinolysis and acquisition of fibrin clot viscoelastic
properties are associated with pulmonary embolism.
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2.1 Abstract
Pulmonary embolism (PE) is a complication of deep vein thrombosis (DVT), although
the cause of embolization remains relatively unknown. Fibrin clot structure and
functional properties have been implicated in the pathology of venous thromboembolism.
However, previous studies investigating the differences in properties between DVT and
PE subjects remain incomplete. The goal of this study was to specifically evaluate fibrin
properties that may contribute to embolization. Clot formation and lysis time, viscoelastic
properties, activated factor XIII (FXIIIa) crosslinking, and clot structure were measured
in the plasma from subjects with acute isolated DVT or PE. Clot formation and lysis time
curves revealed faster lysis time in PE subjects, with no difference in lag time, rate of clot
formation, or maximum absorbance. Compared with DVT, clots derived from PE
subjects showed accelerated establishment of viscoelastic properties, documented by a
decrease in lag time and an increase in the rate of viscoelastic property formation. Rate
and extent of fibrin FXIIIa crosslinking were similar between DVT and PE subjects.
Plasma fibrin clots from PE subjects exhibited lower fiber density compared to DVT.
These data show that clot structure and functional properties differ between DVT and PE
subjects, and may provide insights into possible mechanisms that regulate embolization.
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2.2 Introduction
Deep vein thrombosis (DVT) is a thrombotic disease that mainly affects the large veins of
the lower extremities and pelvis. DVT can result in partial or complete occlusion of
venous circulation. One of the most serious complications of DVT is pulmonary
embolism (PE), which occurs when whole or part of the thrombus embolizes and
becomes lodged within the pulmonary vasculature, partially or completely blocking a
pulmonary artery or branch. Together, DVT and PE comprise the thrombotic disease,
venous thromboembolism (VTE). In contrast to DVT, death is a common outcome in PE
and has been estimated to account for an in-hospital case fatality rate of 23 % (Anderson
et al., 1991). Despite a common pathology relating PE to DVT, a cause for embolization
remains unknown. Evidence does suggest however, that the specific location of the
thrombus in DVT is related to risk of PE. Subjects with distal vein thrombosis, i.e. those
with thrombi localized to only the calf veins, are at very low risk of PE (Moser and
LeMoine., 1981, Kakkar et al., 1969, Moser et al., 1994). This is in contrast to those with
proximal vein thrombosis or thrombi above the knee, who are at high risk for having or
developing PE (Moser and LeMoine., 1981, Kakkar et al., 1969, Moser et al., 1994).
Recent research has focused on the relationship between fibrin clot structure and
functional properties in relation to arterial thrombosis (Collet et al., 2006). Plasma clots
derived ex vivo from subjects with premature coronary artery disease exhibited increased
clot elastic properties, slower lysis, and increased fiber density compared to healthy
controls (Collet et al., 2006). The authors further showed that clot structure and
functional properties were associated with slower lysis and coronary artery disease.
Although most similar studies have focused on arterial thrombosis (Silvain et al., 2011,
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Vadseth et al., 2004, Machlus et al., 2011), some recent efforts have turned to venous
thromboembolism (VTE) (Undas et al., 2009). Plasma clots from VTE subjects exhibited
slower clot lysis time and decreased permeability as compared to relatives without
disease and healthy controls. A sub-analysis of the data also showed that within the VTEpositive population, PE subjects had clots with increased porosity and exhibited faster
lysis rates compared to DVT subjects (Undas et al., 2009). This data indicates that in
VTE, clot structure and the resultant functional properties may be associated with
thrombosis and embolization.
The goal of this study was to further investigate the relationship between fibrin clot
structure and functional properties, expanding on the work by Undas et al. Specifically,
this work evaluated for the first time the viscoelastic properties, clot formation and lysis
time, and factor XIIIa crosslinking of fibrin employing plasma clots derived ex vivo from
acute isolated DVT and PE subjects. Moreover, scanning electron microscopy was used
to evaluate fiber clusters, bundles, density, and heterogeneities in fiber structure between
plasma clots from acute isolated DVT and PE subjects. Differences in the establishment
of viscoelastic properties and lysis time may contribute to embolization in PE subjects
and provide additional insights into the pathways that contribute to pathology in VTE.
2.3 Materials and Methods
We performed a prospective cohort study from January 2010 to March 2012 of subjects
18 years of age or older presenting to the Hospital of the University of Pennsylvania
emergency department with suspected acute DVT or PE. Exclusion criteria included
history of VTE within the prior 4 weeks, unavailable for 90 day follow-up, current use of
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anticoagulants, including any low molecular weight heparins or warfarin, and inability to
provide informed consent. DVT was diagnosed by compression ultrasonography and PE
by computed tomographic pulmonary angiography. Subjects with negative imaging were
contacted by telephone 90 days after enrollment to confirm that they did not develop
clinically apparent VTE. Those who reported development of VTE over this interval
despite initial negative imaging were also considered positive for DVT and/or PE.
Subjects with both distal and proximal vein thrombosis were classified as proximal since
DVT is thought to progress from a distal to proximal location, whereby it is more likely
to embolize (Kakkar et al., 1969). Subjects diagnosed with both DVT and PE were
classified as PE, since a majority of PE cases are thought to arise from DVT (Hull et al.,
1983). Three DVT subjects in our population reported a prior history of PE. These
subjects were not excluded from the study as previous research has shown that 40 % of
DVT subjects without chest symptoms of PE have evidence of PE upon lung scanning
(Moser et al., 1994). Inclusion of these three subjects should bias our analysis towards the
null hypothesis, and thus should not account for any observed differences in functional
properties or structure. Secondary variables were also collected including demographic
information, thrombotic risk factors, comorbidities, and medications. Prior to initiation of
anticoagulant therapy, blood was collected from subjects in 3.2 % sodium citrate (BD
Vacutainer, Franklin Lakes, NJ), and platelet poor plasma was prepared as described
previously (Martinez et al., 2012) and stored at -80 °C. Due to sample volume
limitations, not every patient sample was included in every assay. Because we
hypothesized that functional properties would provide the most insight into the
mechanisms that govern embolization, viscoelastic properties and clot formation and
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lysis time assays were given priority for sample analysis. All samples available were used
for these two assays. Samples for FXIIIa and SEM analysis were chosen at random, and
do not differ in demographic variables or medication use compared with the full study
population. The study design was approved by the Institutional Review Board Involving
Human Subjects at the University of Pennsylvania and written informed consent was
obtained from all study participants.
Fibrinogen concentration
Plasma fibrinogen levels were measured in DVT and PE subjects using an ELISA
developed in our laboratory as previously described (Martinez et al., 2012, Heffron et al.,
2009).
Clot formation and lysis time
Thrombin (0.25 U/ml), CaCl2 (20 mM), and tissue plasminogen activator (tPA) (1.25
μg/ml) (American Diagnostica, Stamford, CT) combined in TBS were simultaneously
added to plasma (0.1 ml, final) from DVT and PE subjects. Changes in turbidity due to
clotting and lysis were monitored spectrophotometrically at 350 nm for 6 hrs. Lag time
was defined as the time for absorbance to change to .01 (OD) (Pieters et al., 2008). The
rate of clot formation was measured as the slope of the linear part of the clot formation
and lysis time curve during the transition from the zero absorbance to the maximum
absorbance. Lysis time was defined as the time difference between the midpoint of the
zero to maximum absorbance transition and the midpoint of the maximum to zero
absorbance transition (Lisman et al., 2005). Clots with higher maximum absorbance are
likely to take longer to lyse. To account for this as well as individual sample variance,
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lysis time was normalized form maximum absorbance (Collet et al., 2006). At a
minimum each sample was measured in duplicate, and curves were averaged using
OriginLab (Northampton, MA).
Viscoelastic properties
Viscoelastic properties were measured with a rheometer (AR-G2, TA Instruments, New
Castle, DE) during plasma clot formation. Plasma clots were produced by the addition of
thrombin (0.25 U/ml) (American Diagnostica, Stamford, CT) and CaCl2 (20 mM)
combined in TBS (0.05 M Tris, 0.14 M NaCl pH 7.4) to plasma (0.1 ml, final) between
the stainless steel stage of the rheometer base and a 40 mm parallel plate. To avoid
drying, the outside of the forming clot was surrounded by mineral oil (3.52 mPa·s)
(Cannon Instrument Company, State College, PA), which is immiscible with plasma. A
time-sweep test was performed for 1 h under an oscillation procedure of 2 % strain at an
angular frequency of 5 radians per second. All measurements were temperature
controlled by a circulating water bath at 25 °C. The storage modulus and the loss
modulus, measures of elastic and viscous properties respectively, were measured at 3 s
intervals. At a minimum each sample was measured in duplicate, and curves were
averaged using OriginLab.
Factor XIIIa crosslinking
Plasma in 10 µl aliquots was clotted with thrombin (0.25 U/ml) and CaCl2 (20 mM). The
reaction was quenched with lithium dodecyl sulfate sample buffer (4X, 25 µl) and
immediately boiled at 100° C for 5 min. Samples were diluted 100 fold and run on a
NuPAGE® 4-12 % Bis-Tris gel (Invitrogen, Carlsbad, CA), followed by western blot
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analysis

with

a

primary

polyclonal

rabbit

anti-human

fibrinogen

antibody

(Dakocytomation, Glostrup, Denmark) and secondary goat anti-rabbit IRDye680®
conjugated IgG antibody (Rockland, Gilbertsville, PA). The blot was viewed and
quantified using the Odyssey infrared imaging system (LI-COR, Lincoln, NE). γ-dimer
and α-polymer formation were normalized as a percent of total γ and α chain,
respectively, at each time point.
Scanning electron microscopy
As described above, thrombin (0.25 U/ml) and CaCl2 (20 mM) were added to plasma
from DVT and PE subjects and allowed to clot for 2 hrs. Clots were then washed, fixed,
dehydrated with serial ethanol dilutions followed by hexamethyldisilazane (Acros
Organics, Fair Lawn, NJ), and sputter-coated with gold palladium as described previously
(Weisel and Nagaswami., 1992). High definition micrographs were taken on a
Philips/FEI XL20 scanning electron microscope (FEI, Hillsboro, Oregon).

Nine to

twelve micrographs were taken for each sample. Fiber density and fiber bundling were
quantified using Image J (Rasband, W.S., ImageJ, U. S. National Institutes of Health,
Bethesda, Maryland, USA, http://imagej.nih.gov/ij/, 1997-2011). For fiber density,
micrographs were overlaid with a 6x6 rectangular grid, with each rectangle being 3x4
µm2 in size. Values were normalized for the number of images taken and are reported as
the mean number of fibers per 3x4 µm2 rectangle ± the standard error (SE). Fiber bundles
and the number of fibers per bundle were counted for each image, resulting in a total area
of 432 µm2. These values were normalized for number of images and are reported as the
mean number of bundles or number of fibers per bundle ± SE.
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Statistics
All continuous variables were tested for Gaussian distribution by D’Agostino and
Pearson omnibus normality test. For parametric distributions, an unpaired t-test was
performed, and Welch’s correction was applied for unequal variances where required.
Values are expressed as the mean ± SE. For nonparametric distributions, Mann Whitney
U test was performed, and the median and the interquartile range (IQR) are reported. For
comparisons between more than two groups, Kruskal Wallis one-way Anova test was
used, followed by testing between groups with Dunn’s multiple comparison test. Values
are expressed as mean ± SE. Correlations were assessed by Spearman rank correlation
analysis. The presence of statistical outliers was determined by Grubb’s outlier test. A pvalue of 0.05 or less was considered statistically signiﬁcant. All statistical calculations
including linear regression analysis were generated and analyzed using GraphPad Prism
(GraphPad Software, La Jolla, CA, USA).
2.4 Results
Study population characteristics
A total of 291 subjects with suspected VTE were recruited for this study. Only subjects
positive for DVT or PE were included for experimental analysis. Of the 100 subjects with
suspected DVT, 32 had a positive ultrasound and an additional 3 were determined to be
positive on 90-day follow-up. Among the 191 subjects with suspected PE, 45 had a
positive computed tomographic pulmonary angiography and 2 additional subjects were
found to have new PE at 90 days. Patient demographics, disease history, risk factors, and
medications are shown in Table 2-1. Significantly more DVT subjects were male
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compared with PE. More DVT subjects had a previous history of peripheral artery
disease, which is a reported risk factor for VTE (Sorensen et al., 2009, Eliasson et al.,
2006). Immunosuppressant use, such as chemotherapeutics and glucocorticosteroids, was
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increased in DVT subjects. Other demographic variables, comorbidities, risk factors, and
medication use were similar between DVT and PE subjects (Table 2-1).
Plasma fibrinogen concentration
Changes in fibrinogen concentration affect fibrin clot properties (Weisel and
Nagaswami., 1992, Roberts et al., 1974). In addition, elevated fibrinogen levels are an
accepted risk factor for arterial thrombosis, and may also play a role in VTE (Benderly et
al., 1996, Folsom et al., 1997, van Hylckama Vlieg and Rosendaal., 2003). We measured
fibrinogen concentration in the plasma of DVT and PE subjects by ELISA (Martinez et
al., 2012, Heffron et al., 2009). Fibrinogen levels were similar between DVT and PE
subjects (DVT: n=34, 5.20 ± 0.43 mg/ml; PE: n=38, 5.93 ± 0.54 mg/ml; p=NS), and did
not differ between distal DVT, proximal DVT, or PE (Distal: n=9, 4.80 ± 0.60 mg/ml;
Proximal: n=25, 5.35 ± 0.55 mg/ml; PE: n=38, 5.93 ± 0.54 mg/ml; p=NS).
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Clot formation and lysis time
Previously published data have shown that
lysis time is faster in PE compared to DVT
subjects

(Undas

et

al.,

2009).

Clot

formation and lysis time were measured in
the plasma of DVT and PE subjects by
spectrophotometry. Lysis time was faster
in PE subjects compared with DVT (Figure
2-1; Table 2-2). The remaining variables of
the clot formation and lysis time curves,
lag time, rate of clot formation, and
maximum absorbance, were similar for
both DVT and PE subjects (Table 2-2).
To further investigate if lysis time might
contribute to embolization, DVT subjects were separated into distal and proximal DVT.
One way Anova analysis showed that mean lysis times were different between the three
groups (Figure 2-1; Table 2-2). Subsequent comparison between groups using Dunn’s
multiple comparison tests shows that lysis time was significantly slower in distal DVT
compared with PE. No other clot formation and lysis time variables differed between
distal DVT, proximal DVT, or PE.
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Viscoelastic properties of fibrin clots
A clot’s inherent viscoelastic properties may determine its ability to withstand shear
forces within the venous lumen. Herein, the storage modulus and the loss modulus, which
represents the elastic and viscous properties respectively, were measured throughout clot
formation. Averaged viscoelastic property curves for DVT and PE subjects are shown in
Figure 2-2. Initial establishment of viscoelastic properties is accelerated in plasma fibrin
clots of PE subjects compared with DVT. Evaluation of individual elastic property curves
obtained from PE subjects show a decrease in the lag time (Figure 2-2; Table 2-3). In
addition, linear regression analysis of averaged curves demonstrates an increase in the
rate of elastic property formation in PE subjects compared with DVT (Figure 2-2; Table
2-3). Similar results were obtained with viscous property curves. Despite differences in
the initial phases of viscoelastic property formation, final elastic and viscous properties
were similar between DVT and PE subjects.
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Factor XIIIa crosslinking of fibrin
We observed increased establishment of viscoelastic properties and faster lysis rates in
clots derived from PE subjects compared to DVT. One possible explanation may be
related to FXIIIa crosslinking of fibrin, which has been shown to increase both the
storage and loss moduli (Ryan et al., 1999), as well as delay lysis time (Lorand and
Jacobsen., 1962, Gormsen et al., 1967). To determine the contribution of FXIIIa
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crosslinking of fibrin to differences seen between DVT and PE subjects, the rate and
extent of formation of γ-dimers and α-polymers were measured in the plasma of DVT
(n=7) and PE (n=12) subjects over a 24 hr. period by western blot analysis. The
formation of γ-dimers and α-polymers were normalized for total γ and α chain,
respectively, at each time point. The rate and extent of γ-dimer formed was similar
between DVT and PE subjects (Figure 2-3). Similar results were found for α-polymer
(Figure 2-3). Correspondingly, loss of γ and α chains of fibrinogen as they became
incorporated into γ-dimers and α-polymers, respectively, were similar between DVT and
PE (data not shown).
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Scanning electron microscopy to evaluate fibrin clot structure
Alterations in fibrin clot structure, including changes in fiber density, diameter, bundling,
and clustering have been associated with risk of thrombosis (Parastatidis et al., 2008,
Collet et al., 2006, Machlus et al., 2011) and are related to lysis rates. Previous studies
have shown that clots derived from PE subjects showed increased porosity compared to
DVT (Undas et al., 2009). Fibrin clot structure was evaluated in 7 DVT and 8 PE subjects
by scanning electron microscopy. Due to their relationship with porosity (Blomback et
al., 1989), fiber density and fiber bundling were quantified from scanning electron
micrographs using Image J (Figure 2-4). Histograms of fiber density display a Gaussian
distribution and show that clots from DVT subjects have a mean of 34.36 ± 0.14
fibers/area2, while PE fibrin clots have a mean of 31.38 ± 0.33 fibers/area2 (p<0.0001;
Figure 2-4). Fiber density was not related to fibrinogen concentration, as Spearman rank
correlation analysis showed no relationship between the two variables (r=0.0071; p=NS).
Histograms of fiber bundling and the number of fibers per bundle were both asymmetric,
and could therefore not be fit with Gaussian distributions (Figure 2-4). Comparison of
means showed that neither fiber bundling (DVT: 3.73 ± 0.30 bundles/area2, n=7; PE: 3.36
± 0.62 bundles/area2, n=8; p=NS) nor the number of fibers per bundle were significantly
different between DVT and PE subjects (DVT: 4.25 ± 0.16 fibers/bundle, n=7; PE: 3.85 ±
0.13 fibers/bundle, n=8; p=NS). Fiber bundling was also not related to fibrinogen
concentration, as Spearman rank correlation analysis showed no relationship between the
two variables (r=-0.1265; p=NS).
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2.5 Discussion
DVT and PE encompass two pathological states of one disease, VTE, and likely have
contrasting risk factors and pathology that define each condition (van Langevelde et al.,
2012). Although much is known about the relationship between clot structure and arterial
thrombosis, less is known about its role in VTE specifically concerning distinctions
between DVT and PE. Furthermore, there is little information about embolization in
general, despite the frequency of this condition and its clinical significance. This study
addresses differences in clot structure and functional properties in this population which
might elucidate properties that are liable to lead to embolization. In this study, both the
storage and loss moduli were established at an earlier time point and at a faster rate in PE
subjects compared to DVT. Plasma fibrin clots from PE subjects also exhibited faster
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lysis times than DVT subjects. FXIIIa crosslinking was similar between DVT and PE
subjects and is thus unlikely to account for the differences in viscoelastic properties and
lysis. We also observed that clots derived from PE subjects exhibit decreased fiber
density compared to DVT. Together these findings suggest that the formation of fibrin
fibers differs between DVT and PE, which are apparent in the final clot structures
determined by scanning electron microscopy. Furthermore, accelerated establishment of
viscoelastic properties occurs in the absence of any observable changes in the rate of clot
formation or lag time by spectrophotometry. This is likely due to the increased sensitivity
of rheometry to detect changes in clot formation compared with spectrophotometry.
Clot formation and lysis are dynamic processes that occur simultaneously (Hoylaerts et
al., 1982). During this process, tPA and plasminogen bind to fibrin, which acts as a
cofactor in the conversion of plasminogen to plasmin (Hoylaerts et al., 1982). Larger
fibrin structures are preferentially targeted compared to smaller ones, allowing for clot
formation to proceed (Hoylaerts et al., 1982). During this process, tPA is limiting
(Bannish et al., Acceptedb, Bannish et al., Accepteda), and clots with a decrease in the
number of fibers being formed will have a higher tPA to fiber ratio. This may account, in
part, for the accelerated rate of lysis in clots with decreased fiber density (Collet et al.,
2000), and may also suggest that in some cases, lysis begins at an earlier time point. The
earlier establishment of viscoelastic properties in PE subjects specifies faster formation of
fiber structures compared to DVT. It is possible that the earlier those structures are
established in PE, the faster lysis can occur, creating instability and embolization prior to
full clot formation. Evidence documenting the time course of initiation of thrombosis to
embolization is lacking in humans, and to date, no animal models of PE from an
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established venous thrombus exist. However, recent studies utilizing intravital
microscopy to monitor real-time thrombus formation in a laser-induced injury model
have shown that embolization can occur as the thrombus is forming, prior to full clot
formation (Neyman et al., 2008, Stolla et al., 2011). This is one possible explanation for
changes seen in the initial, but not the final phases of elastic property formation.
However, if embolization occurs at a time point after the clot has fully formed it is not
clear how differences in viscoelastic properties relate to the tendency to embolize.
Among subjects presenting with acute DVT, identifying those at highest risk for PE could
greatly inform treatment decisions. Although risk factors that characterize those subjects
are lacking, evidence suggests that subjects with proximal vein thrombosis are at much
higher risk of developing PE compared to subjects with distal vein thrombosis (Moser
and LeMoine., 1981, Kakkar et al., 1969, Moser et al., 1994). In a sub-analysis of clot
formation and lysis time properties, distal and proximal DVT subjects were compared for
all clot formation and lysis time variables. Lysis time was significantly faster in PE
compared to distal DVT, but not in proximal DVT. These data could indicate lysis time
as a risk factor for PE. These conclusions must be viewed with caution however, due to
small sample size. Additional studies with a larger population are necessary to confirm
these findings.
In this study we used SEM to visualize clot structure which revealed that fiber density
was decreased in clots from PE subjects relative to DVT, and no differences were seen in
fiber bundling. The decrease in fiber density is consistent with the finding that clot
permeability in PE subjects is increased compared to DVT (Undas et al., 2009). Fiber
density is related to several factors including fibrinogen and thrombin concentration,
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fibrinogen variants, post translational modifications of fibrinogen, and other plasma
constituents (Weisel and Nagaswami., 1992, Parastatidis et al., 2008, Konings et al.,
2011, Herbert et al., 1998, Dang et al., 1989, Langer et al., 1988). Fibrinogen
concentration cannot be the source of changes in fiber density as it was comparable
between DVT and PE subjects, similar to what has been shown in related studies (Undas
et al., 2009). Additional studies are necessary to determine the causative factors that
produce differences in fibrin clot structure, lysis, and viscoelastic properties between
DVT and PE subjects.
In summary, compared with DVT, PE subjects exhibit faster lysis times, possibly due to
lower fiber density, as well as an enhanced establishment of clot viscoelastic properties.
These properties distinguish PE subjects from DVT and may define structural
characteristics that delineate pathologies within VTE and predispose subjects to
embolization.
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Nitrated fibrinogen is a biomarker of oxidative stress in venous
thromboembolism.
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3.1 Abstract
The pathogenesis of venous thromboembolism (VTE) is linked to inflammation and
oxidant production, although specific markers for these pathways with pathological
relevance to VTE have not been explored. The coagulant protein fibrinogen is posttranslationally modified by nitric oxide-derived oxidants to nitrated fibrinogen in both
acute and chronic inflammatory states. Therefore, nitrated fibrinogen may serve as a
marker of inflammation and oxidative stress in VTE. To test this hypothesis we enrolled
subjects (n=251) presenting with suspected VTE at the Hospital of the University of
Pennsylvania emergency department, 50 (19.9 %) of whom were positive by imaging or
90-day follow-up. Mean nitrated fibrinogen was elevated in VTE positive (62.7 nM, 95
% CI 56.6-68.8) compared to VTE negative subjects (54.2 nM, 95 % CI 51.4-57.1; p <
0.01). Subjects in the highest quartile of nitrated fibrinogen had an increased risk of VTE
compared with subjects in the lowest quartile (OR 3.30; 95 % CI 1.25-8.68; p<0.05). This
risk persisted after univariate adjustment for age, active cancer, and recent surgery, but
not after multivariate adjustment. Mean fibrinogen levels measured either by the Clauss
assay or by ELISA were not different between VTE negative and positive subjects. These
data indicate that nitrated fibrinogen is an oxidative risk marker in VTE, providing a
novel mechanistic link between oxidant production, inflammation, and VTE.
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3.2 Introduction
Venous thromboembolism (VTE) is a common thrombotic disease that encompasses both
deep vein thrombosis (DVT) and pulmonary embolism (PE). VTE affects around 1 per
1000 people per year within the United States, with increasing incidence for congenital
and acquired thrombophilic risk factors (Anderson et al., 1991, Salomon et al., 1999,
Pabinger et al., 1992). VTE is a chronic disease with 30 % of patients experiencing a
recurrent event over 10 years (Heit et al., 2000a, Schulman et al., 2006), and is estimated
to account for between 100,000 and 180,000 deaths each year (Rathbun., 2009). Thus,
VTE represents a significant health problem that requires considerable attention.
The precise molecular and biochemical mechanisms of thrombus initiation in VTE
remain unclear. Virchow proposed that changes in blood rheology, induction of a
hypercoagulable state, or endothelial injury are conditions required for venous
thrombosis (Virchow., 1856). More recent studies indicate that inflammation plays an
important role in VTE. However, the interplay between inflammation and Virchow’s
triad is still unresolved. One possibility is that components of the triad activate or damage
endothelial cells within the vein wall resulting in upregulation of receptors for
inflammatory and pro-coagulant molecules. Electron micrographs of early thrombus
formation show leukocyte adhesion to the vein wall (Schaub et al., 1984), presumably
through the binding of P- and E-selectins that are expressed on activated endothelial cells
(Myers et al., 2002, Geng et al., 1990). Leukocytes shed tissue factor-bearing
microparticles, which induce coagulation and the production of a fibrin clot
(Hrachovinova et al., 2003). Neutrophils and monocytes, two of the most prevalent
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leukocytes in venous thrombi, are also able to generate nitrating intermediates, capable of
lipid peroxidation and nitration of proteins (Brennan et al., 2002, Hazen et al., 1999).
One protein known to be modified by tyrosine nitration is the coagulant protein
fibrinogen. Upon activation of the coagulation cascade, circulating plasma fibrinogen is
cleaved by thrombin to fibrin monomers, which polymerize to form a fibrin clot. Recent
studies demonstrate an emerging role for nitrated fibrinogen that links inflammation and
oxidant production to coagulation. Nitrated fibrinogen is elevated in the plasma of
subjects with coronary artery disease (CAD) and in smokers (Vadseth et al., 2004,
Parastatidis et al., 2007). Additionally, in humans injected with small amounts of
lipopolysaccharide, plasma levels of nitrated fibrinogen increase and remain elevated for
at least 72 hrs. post-injection (Heffron et al., 2009). This increase follows an elevation of
circulating myeloperoxidase, an enzyme localized to the azurophilic granules of
neutrophils, which is released during neutrophil activation and is capable of generating
nitrating intermediates (Brennan et al., 2002). Although these data suggest that nitrated
fibrinogen plays a key role linking inflammation, oxidant production, and arterial
thrombotic diseases, its role in VTE remains undefined.
Moreover, nitrated fibrinogen is not simply a marker of inflammation and oxidative
stress, but also has functional effects on fibrinogen and fibrin clotting.

Fibrinogen

nitration was shown to increase the rate of fibrin clot formation, diminish clot lysis rate,
and alter fibrin clot structure and viscoelastic properties (Vadseth et al., 2004, Heffron et
al., 2009, Parastatidis et al., 2007). These functional effects suggest that nitrated
fibrinogen may represent a risk factor for increased thrombotic tendency during
inflammation and oxidant stress. However, the levels of nitrated fibrinogen in VTE have
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not been ascertained. Herein we quantified the levels of nitrated fibrinogen in subjects
presenting to the emergency department with suspected VTE and evaluated if nitrated
fibrinogen is a biochemical risk factor that could explain associations of oxidative stress
and inflammation with thrombotic complications in VTE.
3.3 Materials and Methods
Study population
We performed a prospective cohort study from January 2010 to March 2011 of
consecutive subjects 18 years of age or older presenting to the Hospital of the University
of Pennsylvania emergency department with suspected acute lower extremity DVT or PE.
Exclusion criteria included history of VTE within the prior 4 weeks, unavailable for 90
day follow-up, and inability to provide informed consent. DVT was diagnosed by
compression ultrasonography and PE by computed tomographic pulmonary angiography.
Subjects with negative imaging were contacted by telephone 90 days after enrollment to
confirm that they did not develop clinically apparent VTE. Those who reported
development of VTE over this interval despite negative imaging were also considered
positive for DVT and/or PE. Secondary variables were also collected including,
demographic information, thrombotic risk factors, comorbidities, and medications. Prior
to initiation of anticoagulant therapy in the emergency department, blood was collected
from subjects in 3.2 % sodium citrate (BD Vacutainer, Franklin Lakes, NJ). Blood was
centrifuged at 150 g for 15 min, and the supernatant, platelet rich plasma, was transferred
to a new tube. Platelet rich plasma was then centrifuged at 10,000 g for 10 min to obtain
platelet poor plasma, followed by storage at -80° C for future analysis. Study design was
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approved by the Institutional Review Board Involving Human Subjects at the University
of Pennsylvania and written informed consent was obtained from all study participants.
Plasma nitrated fibrinogen levels
Nitrated fibrinogen levels were measured in plasma using an ELISA described previously
(Heffron et al., 2009). Briefly, 96-well plates were coated with 10 µg/ml antinitrotyrosine antibodies generated and described elsewhere (Heijnen et al., 2006) in 50
mM carbonate buffer pH 9, and incubated at 4 °C under constant rocking overnight. The
next day, plates were washed with 50 mM Tris, 150 mM NaCl, 0.05 % Tween-20 (TBST). Plates were blocked with 3 % bovine serum albumin (BSA) (Roche Diagnostics,
Mannheim, Germany) (wt/vol) in TBS-T for 2 h at 37° C, followed by incubation with 1
% BSA in TBS-T for 1 h at 37° C. A standard curve was created from purified fibrinogen
(American Diagnostica, Stamford, CT) that had been chemically nitrated and the levels of
nitration were independently determined (Heffron et al., 2009). Plasma samples were
diluted (1:10, 1:20) in 1 % BSA in TBS-T, added to the plate in duplicate and incubated 2
h at room temperature under constant rocking. Plates were washed with TBS-T and
coated with 0.3 µg/ml HRP-conjugated rabbit-anti-human fibrinogen polyclonal antibody
(DakoCytomation, Glostrup, Denmark) in 1 % BSA in TBS-T. After 2 h incubation at
room temperature under gentle rocking, the plates were washed with TBS-T and
developed with TMB substrate (KPL, Gaithersburg, MD) followed by quenching of the
reaction with 2 M sulfuric acid (Fisher Scientific, Fair Lawn, NJ). The absorbance was
measured at 405 nm (Molecular devices, Sunnyvale, CA). Nitrated fibrinogen values
were normalized to quality control plasma run with each plate. Each subject sample was
analyzed a minimum of three times and samples that exceeded 15 % coefficient of
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variation were excluded from analysis. The normalized mean intra-assay and inter-assay
variations were 8.23 % and 9.32 %.
Plasma fibrinogen level
Fibrinogen levels were measured in plasma using an ELISA previously described
(Heffron et al., 2009). Ninety-six well plates (Maxisorb, Nunc, Rochester, NY) were
coated with 10 µg/ml mouse anti-fibrinogen monoclonal antibody (Heffron et al., 2009)
in carbonate buffer pH 9, and incubated at 4° C, rocking overnight. The next day, plates
were washed with TBS-T and blocked with 3 % BSA in TBS-T for 2 h at 37° C. A
standard curve was created from purified fibrinogen (American Diagnostica, Stamford,
CT) in TBS-T. Plasma was diluted (1:5000, 1:10000), added to the plate in triplicate, and
incubated for 1 h 37° C. Plates were washed with TBS-T, then coated with 0.3 µg/ml
HRP-conjugated rabbit-anti-human fibrinogen polyclonal antibody (DakoCytomation,
Glostrup, Denmark) in 1% BSA in TBS-T and incubated 1 h at room temperature. The
plate was developed with the TMB peroxidase substrate as described above. Fibrinogen
values were normalized to quality control plasma run with each plate. The normalized
mean intra-assay and inter-assay variations were 11.23% and 14.0%.
Plasma fibrinogen levels were measured by Clauss method (Clauss., 1957) using a
Destiny Max coagulation analyzer according to manufacturer’s protocol (Trinity Biotech,
Co. Wicklow, Ireland).
D-dimer
Plasma D-dimer levels were measured at the Hospital of the University of Pennsylvania
coagulation laboratory using the Vidas ® D-dimer exclusion assay™ (bioMérieux, Lyon,
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France). This assay measures the fibrin degradation product (FDP) D-dimer by an
enzyme linked fluorescence assay. This sandwich ELISA based method uses two antiFDP monoclonal antibodies (P10B5E12C9 and P2C5A10) coupled with fluorescence
detection (de Moerloose et al., 1996, Perrier et al., 1999). In accordance with the
manufacturer’s instructions, a D-dimer level <0.5 μg/ml was considered negative.
The laboratory personnel and technologists performing all assays were blinded to subject
outcome. Laboratory results obtained on the archived plasma samples were not made
available to clinicians or subjects.
Statistics
Gaussian distribution was tested for all continuous variables using D'Agostino & Pearson
omnibus normality test, which indicated non-parametric distributions for all variables
within our data. Thus, comparisons between groups were made using Mann-Whitney U
test. Nitrated fibrinogen, D-dimer, and fibrinogen are given as the mean and the 95 %
confidence interval (CI). The adjusted model for nitrated fibrinogen levels was created
using the generalized linear model, which accounted for demographics, comorbidities,
and VTE risk factors. Odds ratios (OR) were compared by Fishers exact test. Trends in
nitrated fibrinogen levels by quartile were compared by Chi-squared analysis. A p-value
<0.05 was considered statistically significant. All statistical calculations were generated
and analyzed using GraphPad Prism (GraphPad Software, La Jolla, CA), or R-Statistical
package (http://www.r-project.org/).
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3.4 Results
Subject characteristics
A total of 251 subjects were enrolled in this study. Of the 83 subjects with suspected
DVT, 18 had a positive ultrasound and an additional 3 were determined to be positive on
90-day follow-up. Among the 168 subjects with suspected PE, 28 had a positive
computed tomographic pulmonary angiography and 1 additional subject was found to
have new PE at 90 days. Subject demographics, disease history, risk factors, and
medications are shown in Table 3-1. Three well-accepted risk factors for VTE were more
prevalent in the VTE positive subset: advanced age, active cancer, and surgery within the
past 6 weeks. VTE positive subjects were significantly older compared with negative
subjects and were more likely to have active cancer or recent surgery. Thrombophilia
testing was not performed as part of the study. Nevertheless, three subjects reported a
history of hereditary thrombophilia including one with protein C and two with protein S
deficiency. Additionally, two subjects reported having antiphospholipid syndrome. No
other measured demographic variables, comorbidities, risk factors, or medication use
differed between VTE positive and negative subjects (Table 3-1).
Fibrinogen levels in VTE subjects
Fibrinogen levels were quantified by ELISA, which measures fibrinogen antigen, and the
Clauss assay, which measures fibrin clotting time. The mean levels of fibrinogen
compared by Mann Whitney U test were not different between subjects with and without
VTE by either Clauss assay or by ELISA (Figure 3-1). Fibrinogen levels were also
similar between DVT and PE subjects irrespective of the assay employed (Clauss: DVT:
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3.8 mg/ml, 95 % CI 3.0-4.6, n=17; PE: 4.5 mg/ml, 95 % CI 3.6-5.4, n=27; ELISA: DVT:
5.5 mg/ml, 95 % CI 4.4-6.5, n=21; PE: 5.6 mg/ml, 95 % CI 4.7-6.5, n=28). ELISAdetermined fibrinogen levels were higher than those reported by Clauss assay, which is
consistent with findings in previous studies (Kallner et al., 2003).
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Nitrated fibrinogen levels in VTE subjects
Nitrated fibrinogen was measured by an ELISA as described previously (Heffron et al.,
2009). The levels of nitrated fibrinogen were interpolated from a standard curve created
with purified fibrinogen that was chemically nitrated and levels of nitration were
independently determined (Heffron et al., 2009). To ensure the integrity of each assay,
every 96-well plate included a quality control plasma standard, and intra- and inter-assay
variation did not exceed 15 %. The mean levels of nitrated fibrinogen were significantly
higher in VTE positive compared to VTE negative subjects (Figure 3-1). Nitrated
fibrinogen levels were not different between DVT and PE subjects (DVT: 60.9 nM, 95 %
CI 52.3-69.6, n=17; PE: 63.9 nM, 95 % CI 55.2-72.5, n=27).
Previous data indicated that one functional effect of fibrinogen tyrosine nitration was
increased rate of fibrin formation. Since the Clauss assay relies on fibrin clotting time in
plasma to assess fibrinogen levels, Spearman correlation analysis was used to evaluate
the relationship between nitrated fibrinogen and fibrinogen levels (Figure 3-1). Nitrated
fibrinogen correlated linearly with Clauss measured fibrinogen levels (r=0.31, 95 % CI
0.18-0.40, n=207; p<0.0001).
D-dimer levels in VTE subjects
D-dimers are fibrin degradation products that are produced in response to clot lysis by
plasmin, and are used as a diagnostic marker for VTE (de Moerloose et al., 1996,
Bounameaux et al., 1991, Di Nisio et al., 2007, Bozic et al., 2002, Declerck et al., 1987).
D-dimer was measured with the Vidas ® D-dimer exclusion assay™ according to
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manufacturer’s instructions. As expected, mean D-dimer levels were significantly higher
in VTE positive versus VTE negative subjects (Figure 3-1).
Odds ratio for venous thromboembolism across increasing nitrated fibrinogen levels
Cubic spline curves with 95 % CI
(n=226) were constructed to illustrate
the relationship between nitrated
fibrinogen levels and odds ratio of
clinically documented VTE (Figure
3-2). This analysis shows a strong
association

between

nitrated

fibrinogen levels and increased risk
for

VTE

(p<0.005).

A

similar

relationship was found for rates of
VTE across increasing nitrated fibrinogen quartiles (χ2 for trend 7.69; p<0.01) (Table 32). Subjects in the highest quartile were compared with those in the lowest quartile and
were found to have an increased risk of VTE. This risk was maintained after univariate
adjustment for the risk factors found to be elevated in our VTE positive subject
population: advanced age, active cancer, and recent surgery (Table 3-2, models 1, 2, and
3). However, multivariate analysis with these risk factors did not reach statistical
significance (Table 3-2, model 4). This may reflect the small size of our VTE positive
subject population, where additional adjustments reduce the final sample size and
eliminate statistical significance.
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3.5 Discussion
Previous studies have implied that inflammation and oxidative processes may be
mechanistically linked to the pathogenesis of VTE (Wakefield et al., 1995, Nordenholz et
al., 2008, Parastatidis et al., 2008, Brennan et al., 2002, Vadseth et al., 2004, Heffron et
al., 2009, Hazen et al., 1999, Henke et al., 2004, Lo et al., 1995, Eiserich et al., 1998,
Pignatelli et al., 2001). Nitration of proteins and specifically, nitrated fibrinogen has been
quantified in the plasma of subjects that experience inflammatory changes and oxidative
burden (Parastatidis et al., 2008, Vadseth et al., 2004, Heffron et al., 2009). In this study
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the data indicate that oxidants, specifically nitrating intermediates produced in response
to inflammation in VTE, result in nitration of fibrinogen. The levels of nitrated fibrinogen
were significantly elevated in subjects with acute VTE compared to those found to be
negative for the disease. This increase was not dependent on changes in fibrinogen, as
mean levels of fibrinogen were similar between the two groups. Based on previous
studies, the levels of nitrated fibrinogen in VTE negative subjects are higher than would
be expected in healthy non-smoking controls (Parastatidis et al., 2008, Vadseth et al.,
2004). This is likely due to the presence of inflammatory and oxidative conditions in the
VTE negative population, including CAD and smoking that are associated with increased
plasma concentration of nitrated fibrinogen (Parastatidis et al., 2008, Vadseth et al., 2004,
Heffron et al., 2009). Elevated levels of nitrated fibrinogen in VTE, CAD, and smokers
suggest that inflammation and the production of nitric oxide-derived oxidants are present
in thrombotic disorders as well as in those at risk for the disease. Previous research on the
functional effects of nitration on fibrinogen indicates that this modification contributes to
a prothrombotic phenotype (Parastatidis et al., 2008, Vadseth et al., 2004, Heffron et al.,
2009). Thus, nitrated fibrinogen may serve as a comprehensive marker for activation of
inflammatory pathways during thrombosis. Increasing nitrated fibrinogen levels were
positively associated with risk of VTE. When compared with subjects in the lowest
quartile of nitrated fibrinogen, those in the highest quartile had a significantly increased
risk of VTE. This relationship persisted after adjusting individually for the risk factors
that were elevated in the VTE positive group: advanced age, active cancer, and recent
surgery. However, this risk was not maintained after adjusting for the combined factors.
The relatively small VTE positive subject group may account for this difference, whereby
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adjustment reduces the positive group sample size and eliminates statistical significance.
A larger study would be needed to address this. The loss of significance in our
multivariate regression analysis may also suggest that subjects with more than one of
these risk factors also have elevated nitrated fibrinogen levels independent of VTE.
Earlier work has shown that nitrated proteins, including nitrated fibrinogen were
significantly elevated in lung cancer subjects (Pignatelli et al., 2001). Further studies
investigating nitrated fibrinogen in advanced age, various cancer types, and surgical
patients would be necessary to evaluate these effects. Advanced age, malignancy, and the
postoperative state are well-accepted risk factors for VTE (Anderson et al., 1991, Heit et
al., 2000b) and were more prevalent among VTE positive than negative subjects in our
study. Other established risk factors were present in similar proportions among the two
groups, possibly owing to the relatively small size of our study and the small number of
subjects harboring such risk factors.
In this study, nitrated fibrinogen was found to be elevated in the setting of acute VTE. It
remains to be determined whether this elevation reflects an underlying mediator of VTE
pathology or is merely a transient epiphenomenon of acute thrombosis. Studies in which
nitrated fibrinogen levels are measured in those at risk for VTE, as well as in the weeks
and months following an event are needed to address this question, and may provide
valuable information regarding VTE recurrence.
Previous work has revealed that fibrinogen is targeted for oxidative modifications in vivo
(Parastatidis et al., 2008, Vadseth et al., 2004, Heffron et al., 2009, Parastatidis et al.,
2007, Pignatelli et al., 2001). Tyrosine nitration even in the presence of other oxidized
amino acids was shown to significantly accelerate clot formation and factor XIII cross63

linking (Vadseth et al., 2004). Incorporation of nitrated fibrinogen molecules into fibrin
clots was documented by immune-electron microscopy and was found to alter clot
architecture in a dose-dependent manner (Parastatidis et al., 2008, Vadseth et al., 2004).
Changes in structure were accompanied by changes in viscoelastic properties and a
decrease in dissolution by the fibrinolytic systems (Parastatidis et al., 2008, Vadseth et
al., 2004). Removal of the nitrated fibrinogen molecules restored the kinetics of fibrin
clot formation and architecture (Parastatidis et al., 2008). These profound effects on
fibrin clot structure were produced by a relative small fraction of fibrinogen molecules
modified by nitration. Based on previous data and data reported herein, the yield of
nitration represents 1-6 % of fibrinogen molecules (Parastatidis et al., 2008). Kinetic
analysis of fibrin formation revealed that insertion of nitrated fibrinogen molecules
accelerated lateral aggregation, an event that follows the initial nucleation and the
formation of half-staggered, double stranded protofibrils (Doolittle and Pandi., 2006,
Geer et al., 2007, Litvinov et al., 2007). This acceleration is likely due to increased Bknob:b-hole interactions, which are facilitated by the site specific nitration of two
tyrosine residues near the b-hole of the β chain (Parastatidis et al., 2008). Overall, the
concept that 1 nitrated molecule per 100 normal fibrinogen molecules can initiate the
catalytic increase in lateral aggregation is intriguing and consistent with observations
from other proteins that require nucleation events to form protein fibers (Hodara et al.,
2004). These previous studies suggest that the elevated levels of nitrated fibrinogen in
VTE positive subjects would result in an increase in the kinetics of clot formation and
subsequent changes in clot architecture. Additional studies are necessary to address this
hypothesis.
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In addition to nitrated fibrinogen, D-dimer levels were significantly elevated in VTE
positive subjects consistent with previous studies (de Moerloose et al., 1996,
Bounameaux et al., 1991, Di Nisio et al., 2007, Bozic et al., 2002, Declerck et al., 1987).
Sensitivity and specificity for D-dimer at 0.5 µg/ml cutoff in this subject population were
100 % (95 % CI 91.6-100) and 22.3 % (95 % CI 16.1-29.6), respectively and are similar
to what has been previously reported for the Vidas ® D-dimer exclusion assay™ (de
Moerloose et al., 1996, Di Nisio et al., 2007, Freyburger et al., 1998).
Fibrinogen is an independent risk factor and predictor of CAD and associated morbidity
and mortality (Benderly et al., 1996, Folsom et al., 1997). However, its role in VTE
remains unclear. The Leiden Thrombophilia Study (LETS) showed elevated fibrinogen
levels measured by Clauss assay in DVT subjects compared with healthy controls (Koster
et al., 1994). However, in later investigations within LETS, increased risk of DVT with
increasing fibrinogen levels was only found in subjects >45 yrs. In subjects <45 yrs.,
fibrinogen levels in the 95th percentile did not confer increased risk of DVT (van
Hylckama Vlieg and Rosendaal., 2003). Furthermore, in two separate studies in subjects
with suspected PE, the levels of fibrinogen were significantly lower in subjects diagnosed
as positive versus negative for the disease (Kucher et al., 2003b, Kucher et al., 2003a). In
this study, fibrinogen levels were similar between VTE positive and negative groups, and
there were no differences in DVT versus PE subjects. Subject population or sample size
may account for the differences between this study and LETS, where DVT subjects were
compared to a large number of healthy age and sex-matched controls. Likewise, subject
population may also explain the dissimilarity between this study and the two previous
studies investigating fibrinogen in PE (Kucher et al., 2003b, Kucher et al., 2003a).
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Overall, fibrinogen nitration in the VTE subjects certainly reflects active inflammatory
and oxidative states that could favor a pro-coagulant environment resulting in fibrin
structures with altered biochemical and biophysical properties and structure. These
alterations in fibrin clots may profoundly impact the pathology of VTE.
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CHAPTER 4
Summary and Discussion
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4.1 Fibrin clot properties and structure are differentially altered in VTE subjects
Deep vein thrombosis (DVT) and pulmonary embolism (PE) share a common etiology,
but have divergent outcomes. Thus, it is likely that there are coinciding, as well as
distinct characteristics that define each condition (van Langevelde et al., 2012). Previous
studies have shown that alterations in clot structure produce changes in the functional
properties of clots including clot formation, lysis, and viscoelastic properties.
Furthermore, these clot characteristics were also related to risk for arterial thrombosis and
venous thromboembolism (VTE) (Parastatidis et al., 2008, Collet et al., 2006, Undas et
al., 2009). While the cause of embolization remains unknown, it is likely related to the
ability of the clot to withstand the shear forces within the vessel. Thus, alterations in clot
structure may differentiate patients that embolize from those that do not. This is the first
study to evaluate clot structure and functional properties in DVT and PE subjects.
Compared to subjects with isolated DVT, clots formed from PE subjects exhibited
enhanced establishment of viscoelastic properties as evidenced by a decrease in the lag
time and an increase in the rate of both elastic and viscous property formation. In
spectrophotometry assays, clots formed from PE subjects showed a faster lysis time, but
did not differ in lag time, rate of clot formation, or maximum absorbance. Activated
factor XIII (FXIIIa) crosslinking was also similar between the two groups. Fibrin fiber
density was decreased in PE subjects, although fiber bundling remained unaffected.
4.1.1 Fibrinolysis may regulate embolization
Impaired fibrinolysis has been associated with both arterial and venous thrombotic
diseases (Parastatidis et al., 2008, Collet et al., 2006, Undas et al., 2009, Machlus et al.,
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2011). Inability of the body’s own internal mechanisms to clear thrombi can result in
occlusion of vessels and lead to outcomes such as DVT, PE, and myocardial infarction.
This is the proposed mechanism by which elevated levels of circulating fibrinogen
become a risk factor for arterial thrombotic diseases (Machlus et al., 2011). However, the
paradigm appears to take a different course concerning embolic subjects. We observed
faster lysis times in PE subjects compared to DVT. Concomitantly, lysis time was faster
in PE compared to distal DVT, but not proximal DVT, where patients are disposed to
embolization (Moser and LeMoine., 1981, Kakkar et al., 1969, Moser et al., 1994).
Although clot formation and lysis time were not evaluated in a non-VTE population in
this study, previous studies have observed slower lysis rates in both DVT and PE subjects
compared with healthy controls (Undas et al., 2009). Together, these previous studies and
ours suggest that 1) slower lysis alone is a risk factor for thrombosis and 2) changes in
propensity for lysis may predispose a clot towards embolization. These changes may be
due to differences in shear stress, alterations in venous endothelium, or alterations in clot
structure due to local inflammatory or coagulant mediators.
Fibrin clot structure is the most important determinant of lysis rates. Clots composed of
thinner fibers that are more densely packed or heterogeneous clot structures with bundles
or clusters tend to lyse at a slower rate (Collet et al., 2000, Parastatidis et al., 2008). The
converse is also true, where thick fibers that are less densely packed lyse more quickly
(Collet et al., 2000). This is due to the lateral transection of plasmin across fibers as
opposed to lysis from the outside in of individual fibers (Collet et al., 2000). PE subjects
exhibited decreased fiber density compared to DVT, which may account for the faster
lysis observed.
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4.1.2 Clots formed from PE subjects establish viscoelastic properties faster than
DVT
Previous studies evaluating the role of viscoelastic properties in arterial thrombotic
diseases have observed changes in final viscoelastic properties (Collet et al., 2006).
Specifically, clots from premature coronary artery disease subjects have increased elastic
properties i.e. stiffer final clot structure. In this study, clots from PE subjects exhibited
increased rate of the establishment of both the elastic and viscous properties, with no
differences in final viscoelastic properties. To date, no studies have evaluated clot
viscoelastic properties in VTE compared to controls, or between DVT and PE subjects.
Thus, these findings may represent unique clot functional properties involved in
embolization.
Viscoelastic properties are influenced by clot structure. In this study, clots from PE
subjects had decreased fiber density with no differences in bundling and no apparent
cluster formation. Previous studies have shown that clots composed of thinner fibers with
increased fiber density have increased elastic properties (Collet et al., 2006, Roberts et
al., 1974). Heterogeneous clot structures composed of fiber clusters or bundles also tend
to have a higher elastic component (Parastatidis et al., 2008, Bale et al., 1985). Earlier
establishment of viscoelastic properties in PE subjects suggests that there are distinctions
in the fibers formed during clot formation, which is evident by differences in fiber
density by SEM. However, the relationship between viscoelastic properties and clot
structure is complicated by other mediators such as coagulation factors, fibrinogen
variants and post-translational modifications, and will be discussed further below.
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Additional studies will be necessary to address if and how these mediators affect
viscoelastic properties and clot structure in DVT and PE subjects.
Clot formation and lysis are processes of coagulation that occur simultaneously.
Together, tissue plasminogen activator (tPA) and plasminogen bind to fibrin forming a
ternary complex (Hoylaerts et al., 1982). Here fibrin acts a cofactor for the conversion of
plasminogen to plasmin. In addition, tPA and plasminogen preferentially target larger
fibrin structures, which allow coagulation to proceed. The faster rate of establishment of
viscoelastic properties in PE subjects may allow tPA and plasmin to bind and begin lysis
at an earlier time point. This process would likely lead to incomplete or unstable
structures and possibly embolization. Evidence for a mechanism of embolization is
lacking, but studies using intravital microscopy evaluating models of both arterial and
venous thrombosis with nitrogen laser injury have observed embolization as a byproduct
of thrombosis, occurring during thrombus formation rather than after the thrombus has
been established (Neyman et al., 2008, Stolla et al., 2011). This might be one way in
which changes in the initial phases of viscoelastic property formation contribute to
embolization. However, if embolization occurs at a time point after the clot has fully
formed it is not clear how these differences relate to the tendency to embolize.
4.1.3 FXIIIa crosslinking of fibrin does not contribute to differences in fibrin clot
properties
FXIII is a transglutaminase activated by thrombin cleavage of its N-terminal activation
peptide, resulting in FXIIIa crosslinking of fibrin γ and α chains to create γ-dimers and αpolymers, respectively (Nakamura et al., 1975). The main function of FXIIIa crosslinking
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is to provide stability and prevent degradation of the fibrin clot. Clots that are not
crosslinked by FXIIIa are lysed at a faster rate (Lorand and Jacobsen., 1962, Gormsen et
al., 1967). The rate and extent of FXIIIa crosslinking of α and γ chains of fibrin in clots
within our DVT and PE population were evaluated, and no differences were found
between the two groups. Thus, the faster lysis rate observed in clots formed from PE
subjects cannot be attributed to FXIIIa crosslinking of fibrin. However, FXIIIa also
crosslinks α2-antiplasmin (α2-PI) to fibrin, which also delays lysis time (Lorand and
Jacobsen., 1962, Gormsen et al., 1967). Further studies are required to determine if α2-PI
is crosslinked to fibrin in DVT and PE subjects and how this effects lysis time.
FXIII also provides the clot with a large extensibility, and in its absence, protofibrils slide
past one another (Gerth et al., 1974, Brown et al., 2009). Overall, FXIIIa crosslinking
enhances the elastic properties of clots (Gerth et al., 1974, Nelb et al., 1976), which may
have functional consequences on the ability of the clot to withstand shear forces of blood
flow within the vessel. Because FXIIIa crosslinking was similar between DVT and PE
subjects, it is unlikely that the differences in viscoelastic properties are attributed to
FXIIIa crosslinking of fibrin.
4.1.4 Fibrinogen variants, fibrinogen post-translational modifications, and plasma
constituents may contribute to differences between DVT and PE
Although differences in viscoelastic properties, lysis time, and fiber density were
observed between DVT and PE subjects, the cause of these alterations remains unknown.
Fibrinogen concentration, variants, and post-translational modifications, and other plasma
constituents have been shown to affect fibrin clot formation and structure. One of the
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main effectors of fibrin clot structure is fibrinogen concentration. Increased fibrinogen
levels result in faster clot formation, slower lysis, an increased elastic property, and a
dense fibrin meshwork composed of thinner fibers (Weisel and Nagaswami., 1992, Collet
et al., 2006, Machlus et al., 2011). Elevated fibrinogen levels are considered as a risk
factor for arterial thrombosis (Machlus et al., 2011, Benderly et al., 1996, Folsom et al.,
1997), however fibrinogen levels and risk of VTE remain unclear. We and others did not
observe differences in plasma fibrinogen levels between VTE negative and positive
subjects (Martinez et al., 2012, van Hylckama Vlieg and Rosendaal., 2003), or between
DVT and PE. Thus, plasma fibrinogen levels are unlikely to account for the differences
observed between DVT and PE subjects.
A naturally occurring splice variant of the γ chain is γ’, which contains an additional 20
amino acids in place of the last 4 (Wolfenstein-Todel and Mosesson., 1981). About 10 %
of fibrinogen molecules contain γ/γ’ heterodimers, while < 1 % contain γ’/γ’ homodimers
(Mosesson et al., 1972). Clots formed from γ’/γ’ have thinner fibers, smaller pores, more
bundling and free fiber ends (Gersh et al., 2009).The additional 20 amino acids are
negatively charged and contain two tyrosine sulfation sites that increase thrombin binding
affinity, and may account for the antithrombin activity of fibrin (Meh et al., 2001).
Studies have shown that subjects with lower γ’ levels are at increased risk of DVT (Uitte
de Willige et al., 2005). To date, no studies have evaluated γ’ levels in DVT and PE, but
the ratio of plasma γ’/γ fibrinogen may affect clot structure and thus, the propensity for
embolization.
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Fibrinogen is modified by various post-translational modifications including sulfation
(above), homocysteinylation, tyrosine nitration, and oxidation (Vadseth et al., 2004,
Collet et al., 2004, Sauls et al., 2006, Shimizu et al., 1986). Homocysteine (Hcy) is a
sulfur containing amino acid that is involved in the metabolic cycle of methionine.
Homocysteinylation occurs through addition of the Hcy cyclic thioester, Hcy thiolactone
to fibrinogen (Sauls et al., 2006). Twelve homocysteinylated lysines were identified on
all three chains of fibrinogen after incubation of isolated fibrinogen with Hcy thiolactone
(Sauls et al., 2006). These fibrin clots showed fibers with decreased mass to length ratio
and impaired fibrinolysis (Sauls et al., 2006). Further studies will be required to identify
the mechanisms by which Hcy thiolactone affects fibrinogen, and how it relates to VTE.
The effects of tyrosine nitration and oxidation on fibrinogen are discussed at length
below. Briefly, several studies have demonstrated that tyrosine nitration increases fibrin
clot formation (Parastatidis et al., 2008, Vadseth et al., 2004, Heffron et al., 2009, Gole et
al., 2000). While tyrosine nitration is increased in VTE positive subjects compared to
VTE negative subjects, no differences in tyrosine nitration were found between DVT and
PE and it is thus unlikely to account for the differences in clot properties and structure.
Oxidation of fibrinogen delays fibrin clot formation (Vadseth et al., 2004, Zieve and
Solomon., 1966, Inada et al., 1978), but has yet to be evaluated in a VTE population.
DVT and PE subjects both experienced elevated levels of nitrated fibrinogen.
Consequently, oxidation is unlikely to account for differences between DVT and PE
subjects since nitration negates the effects of fibrinogen oxidation (Vadseth et al., 2004).
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Factor XII (FXII) is one of the initial mediators of the intrinsic pathway of the
coagulation cascade, becoming activated (FXIIa) upon exposure to a damaged surface
(Figure 1-1). FXIIa also directly interacts with fibrinogen during clot formation, resulting
in dose-dependent delays in lag time and an increase in fiber density (Konings et al.,
2011). Polyphosphate is a linear polymer of inorganic phosphate that is stored in platelet
dense granules and released upon platelet activation (Ruiz et al., 2004). Polyphosphate
interacts with fibrin to produce thicker fibers, a stiffer clot structure, and delays in lysis,
which were independent of FXIIIa crosslinking (Smith and Morrissey., 2008). Fibrin
interactions with FXIIa, polyphosphate, or other plasma constituents have yet to be
evaluated between DVT and PE, but may have important consequences for clot structure
and tendency to embolize.
4.1.5 Shear rates may affect embolization in proximal veins
Given the increased propensity for embolization in proximal but not distal vein
thrombosis, it is possible that different factors affect local thrombus formation. One
obvious effector might be shear stress, which is related by the formula
where τ is shear stress, µ is viscosity, u is velocity, and δ is the diameter of the vessel. As
the blood is pumped back towards the heart from the lower veins through the upper veins,
vessel segments enjoin and diameter increases. Thus far, no studies have compared shear
stress in the proximal versus distal veins. However, using the formula above, if velocity
and viscosity remain constant while diameter increases due to vessel enjoining, vascular
shear stress should be reduced. Stasis or reduced shear rate is known to cause expression
of adhesion molecules, recruitment of proinflammatory mediators, and secretion of
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coagulation factors (Parmar et al., 2006). These local effectors may thus influence clot
formation or propagation, increasing the tendency to embolize.
4.1.6 Future directions
VTE is a thrombotic disorder that has been thought to progress via endothelial cell
activation, the recruitment of leukocytes, activation of the coagulation cascade followed
by the production of fibrin, and also interactions with platelets (von Bruhl et al., 2012).
Chapter 2 describes differences in fibrin clot structure and functional properties in DVT
and PE subjects, with the goals of further understanding embolization. However, the
coagulation cascade and the production of fibrin are only one component in a complex
processes involving many cell types that play important roles in mediating thrombosis.
Furthermore, fibrin(ogen)-cellular interactions may have consequences for not only fibrin
clot structure, but possibly embolization. Endothelial cells produce tissue factor when
activated, ultimately resulting in the production of the prothrombinase complex for the
cleavage of fibrinogen to fibrin (Grabowski et al., 1993, Campbell et al., 2009).
Fibrinogen co-cultured with TNFα-activated endothelial cell monolayers display fibrin
clot structures that have increased fiber density close to the cells that diminishes with
increasing distance (Campbell et al., 2009). Heterogeneity in fibrin clot structure may
alter lysis rates, where tPA and plasmin lyse clots faster at the periphery and
progressively decrease in speed towards the core. Increased fiber density towards the
endothelium may provide stability during clot formation, whereas clots created by diffuse
tissue factor production may result in clots with diminished fiber density, making them
liable for embolization. Although the direct interaction of neutrophils and monocytes
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with fibrinogen and the resultant effects on clot structure have yet to be determined,
addition of neutrophils prior to clot formation decreased lag time while also diminishing
clot strength (Perrin et al., 2008). In addition, proteins derived from activated neutrophils
such as lysosomal cationic protein, enhanced lateral aggregation of fibrin protofibrils,
increasing fiber diameter (Carr et al., 1986). Thus, variations in local leukocyte
concentration or the proteins that they secrete during activation may influence fibrin clot
structure and stability. Although the interactions between fibrinogen and platelets have
been well studied, their effects on clot structure or embolization are unknown.
Classically, fibrinogen binds to αIIbβ3 on platelets, creating bridges that bind platelet
together (Marguerie et al., 1979). In venous thrombosis, platelets directly interact with
both the endothelium and leukocytes (von Bruhl et al., 2012). Platelet-leukocyte
interactions promote leukocyte recruitment and the releases of neutrophil extracellular
traps (NETs), which are extracellular chromatin fibers and histones that function in this
setting to concentrate procoagulant mediators like tissue factor and FXIIa (von Bruhl et
al., 2012). Fibrin is also concentrated at the NETs, and it remains to be determined what
effects this may have on fibrin clot structure. Again, the concentration of initiating
coagulation factors near the endothelial cell surface could alter fibrin clot density,
ultimately affecting thrombus stability.
Ideally our studies on clot structure in DVT and PE would be extended to an in vivo
model of thrombosis, where all cellular and plasma constituents are present. One possible
model might involve the use fibrinogen deficient (Fg-/-) mice (Iwaki et al., 2002).
Fibrinogen isolated from either DVT or PE subjects would be fluorescently tagged and
injected into Fg-/- mice. Thrombosis would be initiated by a method that does not denude
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the endothelium such as electrical stimulation, and time to thrombus formation, lysis, and
the number of emboli formed could be evaluated by intravital microscopy. In addition,
fibrin clot structure and thrombus cellular composition could be evaluated by SEM and
procoagulant factors and inflammatory mediators could be measured by histology.
Another approach to evaluate the in vivo structure of DVT and PE thrombi would be to
obtain thrombi via either thrombectomy or embolectomy during the course of treatment
or during necropsy. Ideally, thrombi would be collected from distal DVT, proximal DVT,
and PE for a comparison of clot structure and cellular composition during changes in the
propensity for embolization. Although no study has evaluated in vivo thrombi between
DVT and PE patients, some studies have evaluated each separately. Early studies
evaluating the structures of 50 valve-pocket thrombi from the femoral veins of 41 postmortem subjects observed heterogeneity amongst the thrombi collected (Sevitt., 1974).
Some thrombi had little or no cellular invasion. Most others had two main regions, red
areas composed of fibrin and erythrocytes representing the initiating point, and white
areas composed mainly of platelets and fibrin(ogen) representing sites of thrombus
propagation. Thrombus structure has also been evaluated in one PE patient undergoing
embolectomy (Undas et al., 2010). Although there was no comparison group, the
thrombus obtained during embolectomy was in itself heterogeneous, with the inner
thrombus composed of tightly packed thick fibrin fibers and cellular debris, likely from
erythrocytes, and the periphery was composed of many erythrocytes in a thin fibrin
network with few platelets. The authors did not observe the characteristic layering of
‘white’ and ‘red’ thrombi that has been previously described for venous and arterial
thrombi (Sevitt., 1974, Silvain et al., 2011). These data may indicate that not only fibrin
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clot structure, but also cellular constituents may have an effect on propensity for
embolization.
4.2 Nitrated fibrinogen is a biomarker for VTE
VTE is a thrombotic disease where thrombus initiation is characterized by the recruitment
of inflammatory mediators including neutrophils, monocytes and cytokines (von Bruhl et
al., 2012). Neutrophils contain myeloperoxidase (MPO), which is capable of generating
nitrative intermediates (van der Vliet et al., 1997). Previous studies in models of
inflammatory challenge, coronary artery disease, and smokers have found fibrinogen to
be post-translationally modified by reactive nitrogen intermediates, creating nitrated
fibrinogen. Despite the relationship between oxidant production, inflammation, and
thrombosis in VTE, no specific markers encompassing these processes has been
identified. The goal of this study was to evaluate nitrated fibrinogen as a biomarker of
VTE. The study population consisted of subjects presenting with symptoms of VTE to
the emergency department at the Hospital of the University of Pennsylvania. Nitrated
fibrinogen levels were significantly elevated in the plasma of subjects that were found to
be positive for acute DVT or PE. Cubic spline analysis demonstrated a positive
relationship between nitrated fibrinogen levels and odds of VTE. When divided into
quartiles, subjects in the highest quartile of nitrated fibrinogen had increased odds of
VTE compared to subjects in the lowest quartile. This relationship persisted after
univariate regression analysis for those variables that were elevated in VTE positive
subjects: advanced age, active cancer, and recent surgery. However, significance was lost
when the three variables were combined in multivariate regression analysis. These data
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support a role for inflammation and oxidant production in VTE, and establish nitrated
fibrinogen as a biomarker of these processes.
4.2.1 Nitrated fibrinogen levels are elevated in VTE positive subjects
Elevated nitrated fibrinogen levels in VTE positive subjects were not dependent on
changes in plasma fibrinogen concentration as no differences were observed between
VTE positive and negative subjects with either fibrinogen assay. Nitrated fibrinogen
levels were higher in our VTE negative population than in previous studies where VTE
subjects were compared to healthy controls (Parastatidis et al., 2008, Vadseth et al., 2004,
Heffron et al., 2009). Our VTE negative group consisted of subjects that presented with
symptoms of VTE, but were not found to have DVT by compression ultrasound (CUS) or
PE by computed tomographic pulmonary angiography (CTPA). Many of the VTE
negative subjects had previous history of coronary artery disease (CAD), smoking,
infection, and other inflammatory conditions that likely affected nitrated fibrinogen
levels. Because arterial thrombosis, smoking, infection etc. are risk factors for VTE and
have been shown to produce nitrated fibrinogen (Parastatidis et al., 2008, Vadseth et al.,
2004, Heffron et al., 2009), this suggests that nitrative intermediates are produced both in
VTE as well as in those at risk for disease and may ultimately contribute to disease
pathogenesis.
4.2.2 Nitrated fibrinogen is a risk factor for VTE
Cubic spline curves demonstrated a strong, positive relationship between nitrated
fibrinogen levels and odds of VTE. In addition, VTE positive subjects in the highest
quartile of nitrated fibrinogen had an increased risk of VTE compared with those in the
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lowest quartile. Regression analysis showed that this risk persisted after univariate, but
not multivariate adjustment for the variables found to be elevated in the VTE positive
group: advanced age, active cancer, and recent surgery. This suggests that those with
advanced age, active cancer, and recent surgery also experience elevated nitrated
fibrinogen levels independent of VTE. Indeed previous studies have documented elevated
nitrated fibrinogen in lung cancer subjects (Pignatelli et al., 2001). Further studies
evaluating nitrated fibrinogen in advanced age, recent surgery, and other cancer types
will be necessary to address these findings. Alternatively, the loss of significance may be
due to limited numbers within our subject population. Because the VTE positive subject
group is relatively small, adjustment further reduces the sample size and eliminates
statistical significance. Additional studies with a larger population size would be
necessary to address this.
4.2.3 Nitrated fibrinogen may affect clot formation in VTE
Nitrated fibrinogen has been associated with both arterial thrombosis (Vadseth et al.,
2004), as well as those at risk for disease such as smokers (Parastatidis et al., 2008).
Neutrophils and monocytes, which are capable of producing nitrating intermediates, are
key mediators in the initial phases of venous thrombus formation (von Bruhl et al., 2012,
Kakkar et al., 1969, Brennan et al., 2002, Hazen et al., 1999). Furthermore, nitrated
fibrinogen levels increase in response to inflammation (Heffron et al., 2009). The effects
of nitrated fibrinogen remain to be elucidated for VTE, however previous studies have
investigated these effects in vitro (Vadseth et al., 2004) and ex vivo in the plasma of
smokers (Parastatidis et al., 2008). When fibrinogen was nitrated with either 3morpholinosydnonimine (SIN-1), which produces nitric oxide and superoxide that react
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to form peroxynitrite, or with MPO, hydrogen peroxide, and nitrite, a decrease in lag time
and an increase in both the rate of fibrin polymerization and final absorbance was
observed during turbidity assays when compared with unmodified fibrinogen (Vadseth et
al., 2004). Fibrinogen treated with MPO and hydrogen peroxide alone i.e. oxidizing
conditions, produced impairment of fibrin polymerization. Furthermore, oxidized
fibrinogen that was subsequently nitrated resulted in a reversal of the impaired fibrin
polymerization, producing polymerization rates similar to nitration alone. The clot
structure formed from nitrated fibrinogen is composed of thick, twisted fiber bundles and
large pores, which is in contrast to the homogenous structure composed of thin fibers
created from fibrinogen treated with MPO and hydrogen peroxide. Although nitration and
oxidation of fibrinogen produce disparate effects on clot structure, G’ was similar
between the two groups and significantly lower than control, indicating a decrease in clot
stiffness. Although no differences in lysis rate or lysis product formed were seen between
control and nitrated fibrinogen in vitro, injection of microemboli into mice composed of
fibrin treated with SIN-1 followed by bolus injection of tPA showed enhanced lytic
susceptibility compared to emboli of nascent fibrin. No differences were observed
between nitrated and control fibrinogen for fibrinopeptide A (FpA) or B (FpB) release or
FXIIIa crosslinking.
In smokers, elevated nitrated fibrinogen levels showed a dose-dependent increase in the
rate of fibrin polymerization that was reversed when nitrated molecules were removed via
immunoprecipitation with antinitrotyrosine antibodies (Parastatidis et al., 2008).
Scanning electron micrographs showed fiber clustering that was also reversed by
antibody immunoprecipitation. Nitrated fibrinogen levels were positively correlated with
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G’, G”, tan δ, and inversely correlated with fibrinolysis rate. Mass spectrometric analysis
revealed Tyr292 and Tyr422 as nitrated in a majority of the samples analyzed. These
residues are located in the carboxy terminus of the β chain of fibrinogen near the ‘b’ hole.
Use of the ‘B’ knob mimetic peptide accelerated lateral aggregation in all samples, but
was positively correlated with nitrated fibrinogen levels. The effects of in vivo nitration in
smokers show some similarities to the in vitro modified fibrinogen, such as increased rate
of fibrin polymerization. However, there are some disparities between the two studies
(G’, G”, tan δ, clot structure) that might be related to the particular tyrosines that are
susceptible to nitration or the extent of nitration in each system. In this study, nitrated
fibrinogen levels were positively correlated with Clauss-measured fibrinogen levels.
Because Clauss measures fibrinogen based on clotting, this correlation may suggest that
fibrinogen from VTE positive subjects also exhibits gain of function effects for fibrin
polymerization due to nitration. However, VTE subjects might also exhibit unique
functional properties and clot structures that are related to the selectivity and extent of the
tyrosines that are nitrated.
Many of the same pathways that produce nitrating intermediates also produce reactive
oxygen intermediates. Reactive oxygen intermediates have been implicated in vascular
disease pathology and hence, much attention has been paid to the role and function of
oxidative modifications of coagulation factors, especially fibrinogen. In contrast to
nitration, oxidation of fibrinogen by hematoporphyrins, photosensitive dyes, and
chloramines, which release singlet oxygen (1O2), impair fibrin polymerization in a dosedependent manner (Zieve and Solomon., 1966, Inada et al., 1978). Photooxidized fibrin
monomer does not bind fibrinogen as well as nascent fibrin monomer, despite similar
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release of FpA and FpB (Inada et al., 1978). His16, which is located within the ‘B’ knob
site of the Bβ chain of fibrinogen was the only amino acid found to be modified upon
oxidation (Shimizu et al., 1986). Oxidation of fibrinogen also has functional effects on
lysis. Pro-urokinase is activated faster in the presence of oxidized fibrin, and plasmin
lyses oxidized fibrin at a faster rate. This implies a pro-fibrinolytic capacity for oxidized
fibrinogen (Stief., 1993). Overall, the effect of oxidation on fibrinogen appears to be a
loss of function, rather than gain of function as seen with nitration. Nitration levels were
similar between DVT and PE in this study, but oxidation of fibrinogen in VTE has yet to
be determined. Nonetheless, oxidation is unlikely to account for fibrin clot structure and
functional property differences observed between DVT and PE subjects. Because both
DVT and PE patients have elevated nitrated fibrinogen levels, the effect of nitration on
fibrin clot structure and functional properties are likely supersede the effects of oxidation
(Vadseth et al., 2004).
4.2.4 Plasma fibrinogen levels are not associated with VTE
Elevated plasma fibrinogen levels are a risk factor for CAD and its associated morbidity
and mortality (Benderly et al., 1996, Folsom et al., 1997). Some studies have suggested a
similar role for fibrinogen in VTE (Koster et al., 1994). Compared to healthy control
subjects, fibrinogen levels measured by Clauss assay were significantly higher in DVT
subjects, and were thus identified as a risk factor for DVT (Koster et al., 1994). However,
later studies in the same subject population showed that fibrinogen was only a risk factor
for DVT in subjects >45 years of age (van Hylckama Vlieg and Rosendaal., 2003).
Conversely, in PE subjects, plasma fibrinogen levels were found to be lower compared to
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healthy controls (Kucher et al., 2003b, Kucher et al., 2003a). Plasma fibrinogen levels in
this study population were similar between VTE positive and negative subjects, and
between DVT and PE. Discrepancies between this study and others may be due to overall
differences in subject population (Kucher et al., 2003b, Kucher et al., 2003a), or to
differences in the comparison group, where DVT was compared to healthy age and sexmatched controls (van Hylckama Vlieg and Rosendaal., 2003).
4.2.5 Future directions
D-dimer levels were significantly elevated in VTE positive compared with VTE negative
subjects. At an exclusionary cutoff of 0.5 µg/ml, sensitivity and specificity for D-dimer
in this population were 100 % (95 % CI 91.6-100) and 22.3 % (95 % CI 16.1-29.6),
respectively. D-dimer remains the standard non-invasive biomarker for diagnosis of acute
DVT and PE due to its high sensitivity, especially in ELFA and ELISA-based tests (77100 %) (Di Nisio et al., 2007). However, specificity of D-dimer, regardless of test
employed, remains lower and more variable (7-94 %) (Di Nisio et al., 2007). Lack of
specificity for D-dimer requires that many patients undergo unnecessary imaging, which
is both costly and also exposes patients to ionizing radiation in the case of CTPA and
possibly allergy to the contrast agent (Lensing et al., 1990). Identification of a novel
biomarker with specificity to VTE could greatly reduce these concerns. Attempts have
been made to identify such markers. Prothrombin is activated to thrombin by the cleavage
of prothrombin fragment 1+2 (PF 1+2) by the prothrombinase complex containing factors
Xa and Va, Ca2+, and phospholipids. In a study that enrolled 135 consecutive outpatients
with suspected lower extremity DVT, sensitivity of PF 1+2 was 100 %, but specificity
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was only 11 % (Bozic et al., 2002). Similar results with high sensitivity and low
specificity have been found for thrombin-antithrombin III complex, P-selectin, and
VCAM-1 (Bozic et al., 2002). Thus the search remains ongoing for non-invasive
diagnostic markers. Recently, 50 potential biomarkers were evaluated in 304 consecutive
subjects presenting with VTE, 22 of which were positive (Nordenholz et al., 2008). Of
the 50 proteins identified, only D-dimer, c-reactive protein (CRP), and MPO were
potential markers. Further analysis found that MPO in combination with D-dimer did not
increase sensitivity (100 %), but did increase specificity from 59 % to 73 %, which would
have reduced the need for vascular imaging by 13 % (Mitchell et al., 2008). Due to our
small sample size, we did not perform receiver operating characteristic curves or
calculate sensitivity and specificity. However, the identification of MPO as a possible
marker of VTE supports a role for inflammatory and oxidant markers in the diagnosis of
VTE. Our observation that nitrated fibrinogen is a risk factor for VTE may lend itself to
larger studies, pursuing it as a diagnostic marker, possibly in combination with D-dimer
or MPO.
Further evidence for the production of reactive nitrogen intermediates during
inflammation comes from the identification of antibodies that recognize nitrated epitopes
in atherosclerotic lesions and the circulation of CAD patients, as well as in plasma from
acute lung injury patients (Thomson et al., 2007). Furthermore, antigen presenting cells
display nitrated peptides by MHC class II molecule I-A, eliciting a CD4 T-cell response
(Herzog et al., 2005). Although these processes have yet to be evaluated in VTE, the
recognition of nitrated fibrinogen by antinitrotyrosine antibodies and the subsequent
presentation of nitrated epitopes in VTE may represent a novel interplay between oxidant
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production, inflammation, and thrombosis that has not yet been explored. In patients
undergoing vein stripping for primary varicosity, dendritic cells, which are antigen
presenting cells, were observed in patients with varicose veins and/or superficial
thrombophlebitis, but not in vein segments from healthy subjects (Cherian et al., 1999).
Dendritic cells were localized with T-cells and macrophages around areas of
neovascularization. Although this study was performed in superficial thrombophlebitis
and varicose veins, both of these conditions are risk factors for VTE (Heit et al., 2000b,
Decousus et al., 2010). In addition, neovascularization subsequent to thrombosis has also
been observed in a rat model of DVT (Wakefield et al., 1999) and it is probable that
similar innate and adaptive immune responses occur for thrombus resolution in DVT.
Thus, it is possible that nitrated fibrinogen is recognized by antibodies and targeted for
antigen presentation in VTE, resulting in recruitment of adaptive immune cells for
thrombus resolution. Additional studies would be required to address this.
4.3 Risk factors for VTE
Many variables have been associated with risk of VTE including patient demographics,
disease history, and medication use. Previous studies have shown that the risk of VTE
increases exponentially as a function of age, with a relative risk of 1.9 per 10 year
increase (Anderson et al., 1991). In accordance with these and other findings, VTE
positive subjects in this study were older (Table 3-1) and no differences in age were
observed between DVT and PE. In our subject population males were significantly more
prevalent in DVT subjects, whereas females were more prevalent in PE subjects.
Tormene et al. similarly showed that men were at higher risk of isolated DVT and women
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at higher risk of PE (Tormene et al., 2009). However, other studies indicate that DVT is
more prevalent in women and PE in men (Kniffin et al., 1994), while others show no
differences in prevalence between sexes (Anderson et al., 1991, Silverstein et al., 1998).
Thus far it appears that the relationship between sex and risk for either DVT or PE
remains unresolved.
DVT subjects within our population had an increased incidence of peripheral artery
disease compared with PE, despite being a risk factor for both DVT and PE (Sorensen et
al., 2009, Sorensen et al., 2011). In a population based study, subjects with a history of
arterial thrombotic events including myocardial infarction and stroke were at risk for
VTE three months following an event (Sorensen et al., 2009, Sorensen et al., 2011). A
recent study also suggests that heart disease is an independent risk factor for PE in the
absence of venous thrombosis and suggests that PE might also arise from the heart itself
rather than the venous system. If this is the case, clots from these subjects might share
structural characteristics that are similar to arterial clots. Arterial and venous thrombotic
diseases appear to share some, but not all clot structural characteristics (Collet et al.,
2006, Undas et al., 2009) and elucidating differences may help identify factors that
uniquely contribute to each disease, and possibly embolization.
In a cohort of 625 cases of VTE with age and sex-matched controls, malignant neoplasm
increased risk of VTE by 4-fold, with a more than 6-fold increased risk for subjects on
chemotherapy (Heit et al., 2000b). In that same study, surgery increased the risk of VTE
by more than 22-fold (Heit et al., 2000b). Increased incidence of both cancer and surgery
were found for VTE positive subjects in this study (Table 3-1), and incidences were
similar between DVT and PE.

The use of immunomodulatory agents including
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chemotherapeutics are implicated as risk factors for VTE. In a landmark study (Levine et
al., 1988), stage II breast cancer subjects were randomized to either 12 weeks of multi
drug chemotherapy regimen that included cyclophosphamide, methotrexate, fluorouracil,
vincristine, prednisone, doxorubicin plus tamoxifen or a similar 36 week regimen minus
tamoxifen. During the course of treatment, 5 and 9 subjects developed VTE during the
course of either the 12 or 36 week treatment, respectively (Levine et al., 1988). No
thrombotic events occurred before or after the treatment course, implicating a direct
relationship between chemotherapeutics and VTE. Research has also indicated that
treatment of multiple myeloma with either thalidomide or lenalidomide coupled with
dexamethasone increases rates of VTE (Dimopoulos et al., 2007, Rajkumar et al., 2006).
Several subjects in this study reported taking immunomodulators such as prednisone,
vincristine,

fluorouracil,

lenalidomide

and

dexamethasone.

Although

use

of

immunomodulators increases risk of both DVT and PE, in our study DVT subjects
reported a higher use of these agents. Previous studies have indicated that hormonal
contraception or hormone replacement therapies containing estrogen-derivatives are risk
factors for VTE (Gerstman et al., 1990, Daly et al., 1996). In our population, incidences
of hormonal contraception or replacement therapy were similar between VTE negative
and positive subjects and between DVT and PE.
4.4 VTE, antioxidants, and pharmaceutics
Several medications including anti-platelet therapies, statins, and antioxidants that are
used in the treatment of arterial diseases, such as CAD, have also been effective at
reducing the risk of VTE. The effects of these medications may be in part due to lowering
oxidant burden in diseased patients. Given as a prophylactic to hip fracture surgery,
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aspirin lowers the risk of a first DVT by 29 % and PE by 43 % compared with placebo
(Anonymous 2000). Aspirin also attenuates lipid peroxidation and cytotoxicity of bovine
aortic endothelial cells caused by SIN-1-oxidized low-density lipoprotein (Hermann et
al., 1999). Statin use in females reduces the risk of VTE events compared to non-statin
users (relative hazard=.45; P=0.02), and offsets the use of hormone replacement therapy
(relative hazard=1.34; P=0.45) (Herrington et al., 2002). In an interventional study statins
were given to subjects with borderline high (>130 mg/dL) cholesterol for 12 weeks and
nitrotyrosine levels were measured prior to and after statin therapy. Levels of
nitrotyrosine decreased by 25 % following statin use, and were similar in magnitude to
reduction in total cholesterol and low-density lipoprotein particle number (Shishehbor et
al., 2003). The Women’s Healthy Study evaluated the effects of the antioxidant vitamin
E on VTE by randomizing 39,876 women to 600 IU of vitamin E or placebo and
followed them over 10 years (Glynn et al., 2007). Compared to placebo, vitamin E
reduced relative hazard of VTE by 21 %. Antioxidant supplementation of 100 IU/kg
vitamin E and 1 g vitamin C daily diminished neovascularization of the myocardium,
reduced VEGF expression and reduced the amount of nitrotyrosine containing proteins in
hypercholesterolemic pigs (Zhu et al., 2004). Although antiplatelets, statins, and
antioxidant usage were similar between VTE negative and positive subjects, and between
DVT and PE subjects in our cohort, future studies may investigate the relationships
between these medications and their effects on oxidant burden and disease outcome.
In conclusion, these studies show that fibrin clot structure and functional properties differ
between DVT and PE subjects and provide further insight on the mechanisms that govern
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embolization. These studies also identify nitrated fibrinogen as a unique biomarker of
thrombosis, oxidant production, and inflammation in VTE.
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